Friday Program

Education Session | Lunch Debates | EHA / ESH Joint Symposium | Meet-the-Expert | Opening Ceremony | Molecular Hematopoiesis Workshop | Poster Session I

POSTER-WALKS
We would like to invite you to the EHA Poster sessions!
This event was introduced to gain maximum benefit from the scientific work presented and to create a lively interaction and discussion between poster authors, moderators and interested delegates.
Poster-walks will be organized during poster sessions on Friday, June 13 (17:45 – 19:00) and Saturday, June 14 (18:00 – 19:15). The poster area is located behind the exhibition. Poster-walk moderators can be recognized by their cap. We kindly ask you to be in time at the first poster in the poster session of your interest. Drinks and Danish snacks will be served.

POSTER SESSION I
Poster presentation during Poster-walks from 17:45 – 19:00
Poster Area (behind Exhibition)               

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL
Poster-walk Moderator: A Goldstone (University College Hospital, London, United Kingdom)

ACUTE MYELOID LEUKEMIA - BIOLOGY I
Poster-walk Moderator: R Gale (University College London, London, United Kingdom)

ACUTE MYELOID LEUKEMIA - CLINICAL I
Poster-walk Moderator: N Vey (Institut J Paoli Calmettes, Marseille, France)

ANEMIA AND BONE MARROW FAILURE
Poster-walk Moderator: C Dufour (Gaslini Childrens Hospital, Genova, Italy)

CHRONIC LYMPHOCYTIC LEUKEMIA - BIOLOGY AND CLINICAL PROGNOSIS
Poster-walk Moderator: K Stamatopoulos (G. Papanicolaou Hospital, Thessaloniki, Greece)

CHRONIC LYMPHOCYTIC LEUKEMIA - CLINICAL
Poster-walk Moderator: R Rosenquist (Uppsala University, Uppsala, Sweden)

CHRONIC MYELOID LEUKEMIA - BIOLOGY
Poster-walk Moderator: J Goldman (Hammersmith Hospital, London, United Kingdom)

CHRONIC MYELOID LEUKEMIA - CLINICAL I
Poster-walk Moderator: R van Etten (Tufts-New England Medical Center, Boston, USA)

CHRONIC MYELOID LEUKEMIA / MYELOPROLIFERATIVE DISORDERS
Poster-walk Moderator: S Gore (Johns Hopkins University, Baltimore, USA)

CYTOGENETICS AND MOLECULAR DIAGNOSTICS I
Poster-walk Moderator: C Thiede (University Hospital Carl Gustav Carus, Dresden, Germany)

INFECTIOUS DISEASE, SUPPORTIVE CARE
Poster-walk Moderator: J Helweg-Larsen (Rigshospitalet, Copenhagen,Denmark)

MULTIPLE MYELOMA - BIOLOGY
Poster-walk Moderator: N Abildgaard (Odense Universitetshospital, Odense, Denmark)

MULTIPLE MYELOMA – CLINICAL I
Poster-walk Moderator: A Glasmacher (Celgene GmbH, Munchen, Germany)

MYELODYSPLASTIC SYNDROMES - CLINICAL I
Poster-walk Moderator: G Sanz (University Hospital La Fe, Valencia, Spain)

NON-HODGKIN'S LYMPHOMA - BIOLOGY AND CLINICAL
Poster-walk Moderator: C Geisler (Rigshospitalet, Copenhagen, Denkmark)

NON-HODGKIN'S LYMPHOMA - CLINICAL (INDOLENT + MISCELLANEOUS)
Poster-walk Moderator: M Dreyling (University of München-Großhadern, München, Germany)

NOVEL THERAPIES, DRUG RESISTANCE & PHARMACOLOGY I
Poster-walk Moderator: C Zwaan (Erasmus Medical Center, Rotterdam, The Netherlands)

PLATELETS AND THROMBOCYTOPENIA
Poster-walk Moderator: F Rickles (The George Washington University, Washington, USA)

STEM CELL BIOLOGY AND MICROENVIRONMENT
Poster-walk Moderator: S Karlsson (Lund University, Lund, Sweden)

STEM CELL TRANSPLANTATION - DISEASE RELATED
Poster-walk Moderator: J Pérez Simón (Hospital Clinico Salamanca, Salamanca, Spain)

STEM CELL TRANSPLANTATION - MISCELLANEOUS
Poster-walk Moderator: E Morris (University College London, London, United Kingdom)

THROMBOSIS I
Poster-walk Moderator: I Pabinger (Medical University Vienna, Vienna, Austria)

VASCULAR BIOLOGY, BLEEDING DISORDERS AND TRANSFUSION MEDICINE
Poster-walk Moderator: N Avent (University of the West of England, Bristol, United Kingdom)

---

POSTER SESSION I
17:45 - 19:00 hours

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL

0001 DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/­INTOLERANT PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: 24-MONTH DATA FROM START-L
K. Porkka, G. Martinelli, O.G. Ottman, H. Dombret, F.T. Garzon, C. Zhu,
R.A. Larson, B. Simonsson (Helsinki University Central Hospital, Helsinki, Finland)

0002 HIGH DOSE METHOTREXATE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF THE PHARMACOGENETIC POLYMORPHISMS OF RFC1, MDR1 AND MRP2 ON PLASMA CONCENTRATIONS
M. Fakhoury, T. Adam de Beaumais, Y. Medard, D. Zhang, S. Azougagh,
K. Yakouben, E. Jacqz-Aigrain (Robert Debre Hospital, Paris, France)

0003 IMPAIRED DEXAMETHASONE-RELATED INCREASE OF ANTICOAGULANTS IS ASSOCIATED WITH THE DEVELOPMENT OF OSTEONECROSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
M.L. te Winkel, I.M. Appel, R. Pieters, M.M. van den Heuvel-Eibrink (ErasmusMC-Sophia Children's Hospital, Rotterdam, The Netherlands)

0004 REDUCED INTENSITY VERSUS CONVENTIONAL MYELOABLATIVE CONDITIONING (RIC VS. MAC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A SURVEY FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
M. Mohty, M. Mohty, M. Labopin, T. Ruutu, H. De Lavallade, A. Gratwohl,
G. Socie, J. Esteve, R. Tabrizi, A. Nagler, V. Rocha (CHU de Nantes, Nantes, France)

0005 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME: TWO CASES IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
S. Reutenauer, J.F. Albucher, J. Pariente, H. Dumas, O. Milioto,
M. Attal, C. Recher, F. Huguet (CHU Toulouse, Toulouse, France)

0006 EFFICACY AND TOLERABILITY OF INTRATHECAL LIPOSOMAL CYTARABINE FOR TREATMENT OF MENINGEAL RELAPSES IN ACUTE LYMPHOBLASTIC LEUKAEMIA: EXPERIENCE OF A SINGLE PAEDIATRIC INSTITUTION
R. Parasole, G. Menna, N. Marra, A. Mangione, S. Buffardi, A. Misuraca,
F. Petruzziello, V. Poggi (Santobono-Pausilipon Hospital, Naples, Italy)

0007 THE PRESENCE OF CD56/CD16 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA LEADS TO WORSE SURVIVAL AND CORRELATES WITH THE EXPRESSION OF CYTOTOXIC MOLECULES
L.F.F. Dalmazzo, R.H. Jacomo, R.L.G. Cunha, A.F. Marinato,
L.L. Figueiredo-Pontes, A.B. Garcia, E.M. Rego, R.P. Falcão (University of Sao Paulo, Ribeirão Preto - Sp, Brazil)

0008 AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: STILL NOT OUT OF FASHION
F. Folber, M. Doubek, Y. Brychtova, M. Krejci, J. Kujickova, I. Palasek,
B. Weinbergerova, D. Zackova, Z. Koristek, M. Navratil, Z. Racil,
J. Kamelander, D. Dvorakova, J. Mayer (University Hospital Brno, Brno, Czech Republic)

0009 RESULTS OF TREATMENT WITH HYPER-CVAD / MTX-ARA-C, A DOSE-INTENSIVE REGIMEN, IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA AND HIGHLY AGGRESSIVE LYMPHOMA IN A SINGLE CENTER IN CHINA
T. Niu, T. Liu, B.X. Xiang, Y-Q. Jia, H.-l. Zhu (West China Hospital, Sichuan University, Chengdu, sichuan, China)

0010 KINETICS OF CEREBROSPINAL INFILTRATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A FLOW CYTOMETRY STUDY.
M. Ramírez, A. Gómez, C. Martínez, A. Lassaletta, C. Moscardó,
I. Hernández, J. Sánchez de Toledo, T. Molins, A. Muñoz, M. Baragaño,
J.M. Couselo, E. Cela, L. Madero (Hospital Universitario Niño Jesús, Madrid, Spain)

0011 ALL-TRANS RETINOIC ACID PLAYS AN IMPORTANT ROLE IN EARLY RELAPSES PREVENTION IN INFANTS WITH MLL-REARRANGED LEUKEMIA
L. Fechina, E. Shorikov, L. Vakhonina, G. Tsaur, L. Saveliev, A. Popov,
N. Myakova, D. Litvinov, K. Kondratchik, S. Varfolomeeva, T. Zagoskina,
O. Aleinikova, A. Karachunsky, A. Roumiantsev (Regional Children's Hospital, Ekaterinburg, Russian Federation)

0012 OUTCOME OF 198 ADULTS AFTER RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) INCLUDED IN 4 CONSECUTIVE FIRST LINE PETHEMA TRIALS
S. Vives, A. Oriol, M. Tormo, S. Brunet, E. Del Potro, J. Bueno,
J. Bergua, J. Sarrá, C. Grande, C. Bethencourt, J.M. Hernandez-Rivas,
C. Rivas, J.M. Ribera (ICO Badalona-Hospital Germans Trias i Pujol, Badalona, Spain)

0013 METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) GENE POLYMORPHISM IN EGYPTIAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
A.A.G. Tantawy, E.A. El-Bostany, M. Abou El Asrar, A.A.M Adly,
E.A. El-Ghouroury (Faculty of Medicine,Ain Shams University, Cairo, Egypt)

0014 LONG TERM COGNITIVE STATUS AND MAGNETIC RESONANCE IMAGING FINDINGS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
S. Aytac Elmas, S. Aytac, I. Saatci, F. Oktem, M. Cetin, S. Yetgin (Hacettepe University Faculty of Medicine, Ankara, Turkey)

0015 TREATMENT OF MULTIPLY RELAPSED LEUKEMIC MENINGITIS BY HIGH-DOSE INTRAARTERIAL CHEMOTHERAPY
A. Shuvaev, V. Savello, O. Sarjevsky (Military-Medical Academy, Saint-petersburg, Russian Federation)

0016 HYPER-CVAD IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA: AN ANALYSIS OF THE DOSE-INTENSIVE (INDUCTION-CONSOLIDATION) PHASE
P. Silva-Coelho, A. Carneiro, I. Carvalho, F. Principe, J.E. Guimaraes (Hospital de Sao Joao, Porto, Portugal)

---

ACUTE MYELOID LEUKEMIA - BIOLOGY I

0017 SELECTIVE SILENCING OF THE NPM1 MUTANT PROTEIN AND APOPTOSIS INDUCTION UPON ATRA IN VITRO TREATMENT OF AML CELLS CARRYING NPM1 MUTATIONS

1. Martelli, V. Pettirossi, N. Manes, F. Susta, P.L. Orvietani, A. Liso,
2. Mezzasoma, F. Cecchetti, M.F. De Marco, B. Bigerna, A. Pucciarini,
3. Nicoletti, L. Binaglia, C. Mecucci, M.F. Martelli (Hematology Department, Perugia, Italy)

0018 MIRNA EXPRESSION IN ACUTE MYELOID LEUKEMIA CELLS WITH DIFFERENT KARYOTYPES
S. Brundiers, S. Brundiers, K. Battmer, M. Brugman, M. Castoldi,
J. Krauter, M. Muckenthaler, A. Ganser, M. Eder, M. Scherr (Hannover Medical School, Hannover, Germany)

0019 AML1/RUNX1 MUTATIONS ARE FREQUENT IN DE NOVO AML WITH CERTAIN CYTOGENETICS AND COOPERATING MOLECULAR MUTATIONS DIFFER DEPENDENT ON UNDERLYING CYTOGENETICS
S. Schnittger, F. Dicker, W. Kern, T. Haferlach, C. Haferlach (MLL Munich Leukemia Labortory, Munich, Germany)

0020 HIGH INDO (INDOLEAMINE 2,3-DIOXYGENASE) MRNA LEVEL IN BLASTS OF ACUTE MYELOID LEUKEMIC PATIENTS PREDICTS POOR CLINICAL OUTCOME
M.E.D. Chamuleau, A.A. van de Loosdrecht, C.J. Hess, A. Zevenbergen,
J.J.W.M. Janssen, R. Delwel, P.J.M. Valk, B. Lowenberg,
G.J. Ossenkoppele (VU University Medical Center, Amsterdam, The Netherlands)

0021 FARNESYLTRANSFERASE INHIBITOR SYNERGISTICALLY INCREASES RAPAMYCIN-INDUCED CELL GROWTH INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS J.-W. Cheong, H.W. Lee, J.I. Eom, J.S. Kim, Y.H. Min (Yonsei University College of Medicine, Seoul, South-Korea)

0022 PIN1 IS UPREGULATED IN ACUTE MYELOID LEUKEMIA WITH C/EBPALPHA MUTATIONS AND BLOCKS GRANULOCYTE DIFFERENTIATION VIA C-JUN
J.A. Pulikkan (LZG AG BEHRE, Halle, Germany)

0023 GENOME-WIDE PROFILING OF DNA COPY NUMBER ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA (AML) USING HIGH DENSITY SINGLE NUCLEOTIDE POLYMORPHISM ARRAY
I. Iacobucci, E. Ottaviani, A. Astolfi, F. Salmi, N. Testoni, S. Luatti,
C. Papayannidis, P. Giannoulia, F. De Rosa, S. Paolini, P.P. Piccaluga,
D. Cilloni, A. Pession, M. Baccarani, G. Martinelli (Department of Hematology/Oncology "Seràgnoli", Bologna, Italy)

0024 TREATMENT WITH PAN DEACETYLASE (DAC) INHIBITOR PANOBINOSTAT (LBH589) DEPLETES EZH2 AND DNMT1, DEREPRESSES JUNB AND SENSITIZES ACUTE MYELOID LEUKEMIA CELLS TO DECITABINE
W. Fiskus, Y. Wang, R. Rao, P. Atadja, K.N. Bhalla (Medical College of Georgia Cancer Center, Augusta, USA)

0025 DETECTION OF PROTEINASE 3 (PR3) GENE OVEREXPRESSION AND NUCLEAR DELOCALIZATION IN CBF ACUTE MYELOID LEUKEMIAS
D. Cilloni, S. Carturan, I. Defilippi, R. Catalano, E. Messa, A. Rotolo,
P. Nicoli, I. Iacobucci, G. Martinelli, E. Bracco, A. Levis, G. Saglio (University of Turin, Turin, Italy)

0026 CXCR-4 POSITIVE ACUTE MYELOID LEUKEMIAS (AGE < 60 YEARS): IMMUNOPHENOTYPIC, CYTOMORPHOLOGIC, CYTOGENETIC, AND MOLECULAR CHARACTERISTICS
U. Oelschlaegel, B. Mohr, U. Schaekel, F. Kroschinsky, M. Schaich,
G. Ehninger, C. Thiede (University Hospital Dresden, Dresden, Germany)

0027 FLT3 INTERNAL TANDEM DUPLICATION INVOLVING ITS UBIQUITIN DEPENDENT ENDOCYTOSIS MOTIF SUSPEND MODULATION BY HDM2 AND ARE ASSOCIATED WITH INFERIOR SURVIVAL IN AML
L. Wergeland, E. Oveland, S. Gry, S.L. Bedringaas, R. Hovland, Ø. Bruserud, B.T. Gjertsen (University of Bergen, Bergen, Norway)

0028 MICRORNA PROFILING OF EVI1 DEREGULATED MYELOID LEUKEMIA
A. De Weer, B. Poppe, P. Mestdagh, P. Van Vlierberghe, N. Van Roy,
A. De Paepe, B. Verhasselt, J. Vandesompele, F. Speleman (University Hospital, Centre for Medical Genetics, Ghent, Belgium)

0029 CLASS II-ASSOCIATED INVARIANT CHAIN PEPTIDE (CLIP) EXPRESSION ON AML BLASTS NEGATIVELY AFFECTS ANTI-LEUKEMIC IMMUNITY BY INTERFERING WITH CD4+ T CELL RECOGNITION

1. van Luijn, M.E. Chamuleau, T.M. Westers, J.A. Thompson,
2. Ostrand-Rosenberg, A. Zevenbergen, G.J. Ossenkoppele,

S.M. Van Ham, A.A. Van de Loosdrecht (VU Medical Center, Amsterdam, The Netherlands)

0030 THE ROLE OF C-FLIP IN ACUTE MYELOID LEUKAEMIA
D.P. McLornan, M.F. McMullin, K.I. Mills, P.G. Johnston, D.B. Longley (Queen'S University Belfast, Belfast, Northern Ireland)

0031 IMMUNOGLOBULIN AND T CELL RECEPTOR REARRANGEMENTS IDENTIFICATION REVEALS POTENTIALLY NEW SUBGROUP WITHIN PEDIATRIC ACUTE BIPHENOTYPIC LEUKEMIAS
J. Volejnikova, E. Mejstrikova, E. Fronkova, T. Valova, L. Reznickova,
J. Zuna, J. Stary, O. Hrusak, J. Trka (2nd Medical School, Charles University Prague, Prague, Czech Republic)

0032 GENE TARGETS OF 11Q23 AMPLIFICATION AND CONCOMITANT 5Q DELETION IN AML/MDS CELLS
B. Schneider, R. Geffers, H. Quentmeier, M. Kaufmann, S. Nagel,
H.G. Drexler, R.A.F. MacLeod (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany)

0033 PANOBINOSTAT (LBH589) + DOXORUBICIN: A PRECLINICALLY SYNERGISTIC COMBINATION AGAINST ACUTE MYELOID LEUKEMIA (AML) CELL LINES REPRESENTING A CLINICALLY PROMISING COMBINATION FOR PATIENTS WITH AML
P. Maiso, E.M. Ocio, E. Colado, M. Garayoa, P. Atadja, A. Pandiella,
J.F. San Miguel (Universidad de Salamanca, Salamanca, Spain)

0034 ABT-737 TARGETS THE COOPERATION OF BCL2 AND ONCOGENIC NRAS IN AN IN VIVO MULTI-STEP MODEL OF ACUTE MYELOID LEUKAEMIA
S. Beurlet, N. Omidvar, C. Le Pogam, F. Herventin, L. Sarda-Mantel,
P. Merlet, A. Janin, C. Leboeuf, M.E. Noguera, A. Soulie, N. Setterblad,
M. Pla, M. Konoplova, M. Andreef, C. Chomienne, R.A. Padua (Inserm, Paris, France)

---

ACUTE MYELOID LEUKEMIA - CLINICAL I

0035 A DOUBLE BLIND PLACEBO-CONTROLLED RANDOMIZED PHASE III STUDY OF HIGH DOSE CONTINUOUS INFUSION CYTOSINE ARABINOSIDE (ARAC) WITH OR WITHOUT VNP40101M (CLORETAZINE®) IN PATIENTS WITH FIRST RELAPSE OF ACUTE MYELOID LEUKEMIA (AML)
N. Norbert, A. Pigneux, D. Boscovic, J. Kell, T. Robak, P. Staib, B. Johnson,
S. O'Brien, F. Giles (Institut Paoli-Calmettes, Marseille, France)

0036 A PHASE I STUDY WITH CP-4055 IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES

1. Giles, S.M. O'Brien, N. Vey, D. Rizzieri, J. Sarantopoulos, T. Prebet,
2. Ravandi, S. Faderl, A. Charbonnier, T.F. Jacobsen, B.O. Nilsson,
3. Staudacher, H.M. Kantarjian (CTRC at the University of Texas Health Science Center San Antonio, San Antonio, Texas, USA)

0037 REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): LONG TERM RESULTS OF A “DONOR” VERSUS “NO DONOR” COMPARISON
M. Mohty, M. Mohty, H. De Lavallade, J. El-Cheikh, P. Ladaique,
C. Faucher, S. Fürst, N. Vey, D. Coso, A.M. Stoppa, J.A. Gastaut,
C. Chabannon, D. Blaise (CHU de Nantes, Nantes, France)

0038 PHASE I STUDY OF F60008, A TRIPTOLIDE DERIVATIVE, IN PATIENTS WITH REFRACTORY OR RELAPSING ACUTE LEUKEMIAS
J.L. Harousseau, H. Dombret, A. Pigneux, M. Michallet, M. Brandely (University Hospital, Nantes, France)

0039 A NEW PROGNOSTIC MODEL FOR PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA: RESULTS OF THE DSIL AML96 TRIAL
M. Schaich, W.E. Aulitzky, H. Bodenstein, M. Bornhäuser, T. Illmer,
U. Schäkel, N. Schmitz, S. Soucek, C. Thiede, H. Wandt, G. Ehninger (Universitätsklinikum C.G. Carus, Dresden, Germany)

0040 ACCURATE PREDICTION OF CYTOGENETIC SUBGROUPS IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH GENE EXPRESSION PROFILING; A CRITICAL VALIDATION STUDY
B.V. Balgobind, M.M. van den Heuvel-Eibrink, R.X. Menezes, D. Reinhardt,

1. Hollink, T.J.C.M. Arentsen-Peters, E. van Wering, G.J.L. Kaspers,
2. Cloos, E. de Bont, J. Cayuela, A. Baruchel, J. Trka, J. Stary, R. Pieters,

C.M. Zwaan, M.L. den Boer (Erasmus MC - Sophia's Children Hospital, Rotterdam, The Netherlands)

0041 FLOW-CYTOMETRIC MINIMAL RESIDUAL DISEASE DETERMINATION IS A SURROGATE PROGNOSTICATOR IN ADULT AML PATIENTS WITH NORMAL KARYOTYPE
F. Buccisano, L. Maurillo, G. Del Poeta, M.I. Del Principe, D. Fraboni,
P. Panetta, M. Irno Consalvo, M. Rizzo, L. Giannì, S. Campagna,
S. Faccia, D. Renzi, M. Postorino, M. Cantonetti, F. Lo Coco,
S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy)

0042 IMPACT OF DIFFERENT POSTREMISSION STRATEGIES ON QUALITY OF LIFE ACCORDING TO AGE AND AFFECTED LIFE CYCLE PHASE AT INITIAL DIAGNOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

1. Schlenk, K. Döhner, M. Schlosser, S. Groner, D. Späth, R. Hann,
2. Messerer, J. Krauter, I. Schäfer, A. Ganser, H. Döhner (University of Ulm, Ulm, Germany)

0043 IMPACT OF KIT MUTATIONS IN ACUTE MYELOID LEUKAEMIA WITH INV(16)

1. Cairoli, A. Beghini, C.B. Ripamonti, G. Grillo, G. Nadali, E. Di Bona, P. Colapietro, G.B. Bertani, E. Ravelli, G. Nador, C. Castagnola, C Cattaneo, E. Ottaviani, P. Pioltelli, A. Viola, A. Cuneo, F. Ferrara,
2. Martinelli, M. Lazzarino, G. Rossi, G. Pizzolo, E. Morra (Niguarda Hospital, Milan, Italy)

0044 GENTUZUMAB-OZOGAMICIN (GO) PLUS IDARUBICIN (I) AND CYTARABINE (C) AS INDUCTION TREATMENT FOR ELDERLY PATIENTS WITH POOR-RISK CYTOGENETICS ACUTE MYELOID LEUKEMIA (AML),RESULTS OF GOELAMS LAMR04 STUDY
J. Delaunay, C. Recher, N. Vey, F. Witz, B. Lioure, O. Tournilhac,
C. Himberlin, D. Bouscary, N. Ifrah, J.L. Harousseau (University Hospital of Nantes, Nantes, France)

0045 PHASE II PILOT TRIAL OF GEMTUZUMAB OZOGAMICIN (MYLOTARG) IN COMBINATION WITH FLUDARABINE, CYTARABINE, IDARUBICIN (FLAI) AS INDUCTION THERAPY IN CD33-POSITIVE AML PATIENTS YOUNGER THAN 65 YEARS
A. Candoni, G. Martinelli, M. Tiribelli, E. Simeone, E. Toffoletti,
A. Michelutti, A. Chiarvesio, M. Malagola, P.P. Piccaluga, D. Russo,
R. Fanin (Division of Hematology, Udine, Italy)

0046 FACTORS INFLUENCING CLINICAL DECISION MAKING IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML). REPORT ON 340 CONSECUTIVE PATIENTS JUDGED AS UNFIT TO RECEIVE INTENSIVE INDUCTION CHEMOTHERAPY
F. Ferrara, S. Palmieri, G. Gianfaldoni, F. Leoni (Cardarelli Hospital, Naples, Italy)

0047 PEGFILGRASTIM IN PATIENTS WITH AML OLDER THAN 60 YEARS. AN ANALYSIS OF THE AML97#38 AND AML2004#69 STUDIES OF THE EAST GERMAN HAEMATOLOGY AND ONCOLOGY STUDY GROUP (OSHO)
H.K. Al-Ali (University of Leipzig, Leipzig, Germany)

---

ANEMIA AND BONE MARROW FAILURE

0048 THE OUTCOME OF PATIENTS =60 YEARS WITH ACQUIRED APLASTIC ANEMIA TREATED WITH IMMUNOSUPPRESSIVE THERAPY (IST): NO DIFFERENCE IN RESPONSE RATE AND SURVIVAL BETWEEN STANDARD VERSUS ATTENUATED IST
Y. Kao, W. Xu, J.M. Brandwein, J.H. Lipton, H.A. Messner,
M.D. Minden, A.C. Schuh, A.D. Schimmer, K. Yee, V. Gupta (Princess Margaret Hospital, Toronto, Canada)

0049 DEVELOPMENT OF A DISEASE SEVERITY SCORING SYSTEM FOR TYPE 1 GAUCHER DISEASE

1. Cappellini, T. Cox, E.H. Giannini, G.A. Grabowski, W.L. Hwu,
2. Mankin, A.M. Martins, C. Sawyer, S. Vom Dahl, N. Weinreb, M. Yeh,
3. Zimran (University of Milan, Milano, Italy)

0050 DEFICIENCY OF RED CELL BOUND CD55 AND CD59 IN PATIENTS WITH RHEUMATOLOGICAL DISORDERS
A. Sarantopoulos, E. Terpos, S. Masouridi, J. Stavropoulos,
G. Karagiannidis, P. Konstantopoulou, C. Antoniadis, G. Vaiopoulos,
J. Meletis (Second Blood Transfusion Center, Laikon General Hospital, Athens, Greece)

0051 DETECTION OF CIRCULATING ANTI-ERYTHROPOIETIN ANTIBODIES IN PATIENTS WITH END STAGE RENAL DISEASE ON REGULAR HEMODIALYSIS
M. Attia, M. Eldin, M. Labib, A. Omer (Faculty of Medicine - Ismailia University, Ismailia, Egypt)

0052 FLOW-CYTOMETRIC ANALYSIS OF BONE MARROW GRANULOCYTIC PROGENITOR/PRECURSOR CELLS IS A USEFUL TOOL FOR ESTABLISHING THE DIAGNOSIS OF CHRONIC IDIOPATHIC NEUTROPENIA
H. Koutala, M. Velegraki, M. Ximeri, G. Gvazava, M. Psyllaki,
C. Kalpadakis, G. Eliopoulos, H. Papadaki (University of Crete School of Medicine, Heraklion, Crete, Greece)

0053 PRESENCE OF THREE POINT MUTATIONS IN THE ELA2 GENE OF A PATIENT WITH SEVERE CONGENITAL NEUTROPENIA (SCN)
M. Lanciotti, G. Caridi, S. Pigullo, T. Lanza, C. Dufour (G. Gaslini Institute, Genova, Italy)

0054 QUANTITATIVE EXPRESSION OF CD64 ON NEUTROPHIL GRANULOCYTES AS EARLY MARKER OF SEPSIS OR SEVERE INFECTION
G.B. Lobreglio, P. D'Aversa, L. Leo, S. Scolozzi, G. Fiore
(A.O. "Card G. Panico", Tricase, Italy)

0055 ALTERATIONS OF MESENCHYMAL STROMAL CELLS IN PATIENTS WITH APLASTIC ANEMIA
V. Petrova, N. Nifontova, A. Mikhaylova, J. Drize (National Hematology Research Centre, Moscow, Russian Federation)

0056 MULTIFOCAL LANGERHANS CELL HISTIOCYTOSIS IN ADULTS. SINGLE CENTER EXPERIENCE
D. Bogdanovic, M. Cemerikic Martinovic, D. Jovanovic Perunicic,
N. Bogunovic, B. Milenkovic, M. Pavlovic, L. Medenica, P. Kendereski,
R. Colovic, P. Mandaric, D. Colovic (Institute of Hematology CCS, Belgrade, Serbia)

0057 HIGH PROPORTION OF MIXED CHIMERISM WITH T-CELL DEPLETED PERIPHERAL STEM CELL TRANSPLANTS FOLLOWED BY T-CELL ADD-BACK IN PATIENTS WITH APLASTIC ANEMIA
F. Verholen, E. Levrat, E. Roosnek, M. Terrettaz, C. Helg, J.R. Passweg,
C. Chalandon (Service d'hématologie, Genève, Switzerland)

0058 IDENTIFICATION OF NEW RPS19 DELETIONS IN DIAMOND­BLACKFAN ANEMIA USING THE MLPA TECHNIQUE
P. Quarello, E. Garelli, A. Carando, M.F. Campagnoli, A. Brusco,
P. Pappi, M. Barberis, I. Dianzani, U. Ramenghi (Hematology Unit, Pediatric Department, University of Torino, Torino, Italy)

0059 ASYMPTOMATIC CEREBRAL MICROBLEEDS IN PATIENTS WITH APLASTIC ANEMIA
S. Sharma, P. Malhotra, V. Lal, P. Singh, N. Varma, S. Varma (Post Graduate Institute of Medical Education and Research,(PGIMER), Chandigarh, India)

0060 ENERCA2, THE EUROPEAN NETWORK AIMED AT IMPROVING THE DIAGNOSIS, EPIDEMIOLOGICAL KNOWLEDGE AND MEDICAL EDUCATION ON RARE AND CONGENITAL ANAEMIAS
P. Aguilar-Martinez, On behalf of the ENERCA2 (CHRU de Montpellier, Montpellier, France)

0061 SEVERE IRON OVERLOAD IN TRANSFUSION DEPENDENT DIAMOND BLACKFAN ANEMIA PATIENTS
P. Quarello, S. Roggero, T. Vinciguerra, F. Longo, M. Borri, A. Piga,
U. Ramenghi (University of Torino, Torino, Italy)

0062 PULSED DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA
F.R. Mauro, I. Del Giudice, S. Coluzzi, D. Armiento, M.S. De Propris,

1. De Nicolo', M.C. Arista, L. Quattrocchi, M.G. Mazzucconi,
2. Girelli, R. Foa' (University "La Sapienza", Rome, Italy)

0063 IMPROVEMENT OF HEMOGLOBIN LEVEL AND REDUCTION OF TRANSFUSION REQUIREMENT IN FOUR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES AND PRIMARY MYELOFIBROSIS RECEIVING DEFERASIROX TREATMENT
E. Messa, R. Catalano, F. Messa, F. Arruga, I. Defilippi, S. Carturan,
A. Rotolo, D. Gioia, A. Roetto, E. Bracco, A. Levis, C. Camaschella,
D. Cilloni, G. Saglio (University of Turin, Turin, Italy)

---

CHRONIC LYMPHOCYTIC LEUKEMIA - BIOLOGY AND CLINICAL PROGNOSIS

0064 P53 MUTATIONS IN A LARGE COHORT OF CLL PATIENTS WITH 17P DELETION: DETAILED ANALYSIS OF MUTATION PROFILE, ALTERNATIVE MECHANISMS OF INACTIVATION, CLONE SIZE AND CLONAL EVOLUTION.
T. Zenz, T. Denzel, S. Häbe, J. Mohr, D. Winkler, A. Bühler, N. Patten,
S. Truong, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0065 GENOME-WIDE DNA ANALYSIS IDENTIFIES RECURRENT IMBALANCES PREDICTING OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
F. Forconi, A. Rinaldi, I. Kwee, E. Sozzi, D. Raspadori, P. Rancoita,
D. Rossi, C. Deambrogi, D. Capello, E. Zucca, D. Marconi, R. Bomben,
V. Gattei, F. Lauria, G. Gaidano, F. Bertoni (University of Siena, Siena, Italy)

0066 HIGH-RESOLUTION SNP-ARRAY PROFILING OF CHRONIC LYMPHOCYTIC LEUKEMIA
J. Edelmann, C. Schwänen, K. Holzmann, S. Stilgenbauer, H. Döhner (Universitätsklinikum Ulm, Ulm, Germany)

0067 COMMON HERPESVIRUSES AND CHRONIC LYMPHOCYTIC LEUKEMIA: MOLECULAR EVIDENCE FOR A POTENTIAL LINK WITH A SUBSET OF PATIENTS EXPRESSING STEREOTYPED IGHV4-34 B CELL RECEPTORS
E. Kostareli, A. Hadzidimitriou, N. Stavroyianni, N. Darzentas,
A. Athanasiadou, M. Gounari, V. Bikos, A. Agathaggelidis,
T. Touloumenidou, I. Zorbas, A. Kouvatsi, N. Laoutaris, A. Fassas,
A. Anagnostopoulos, C. Belessi, K. Stamatopoulos (G. Papanicolaou Hospital, Thessaloniki, Greece)

THE RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY (RHAMM): CHARACTERIZATION OF AN IMMUNOTHERAPEUTICAL TARGET WHICH IS ASSOCIATED WITH PROLIFERATION AND SHOWS PROGNOSTIC VALUE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) PATIENTS
K. Giannopoulos, K. Giannopoulos, A. Buehler, D. Mertens, T. Barth,
I. Idler, A. Kroeber, J. Greiner, A. Dmoszynska, J. Rolinski, H. Doehner,
S. Stilgenbauer, M. Schmitt (Medical University of Lublin, Lublin, Poland)

0069 CCL3 CCL4, THE MAJOR CHEMOKINES PRODUCED BY CD38+ CLL CELLS, FACILITATE MICROENVIRONMENTAL INTERACTIONS OF NEOPLASTIC CELLS VIA THE CD49D/VCAM PAIR
A. Zucchetto, D. Benedetti, R. Bomben, C. Tripodo, F. Bossi, M. Dal Bo, D. Marconi, M. Degan, G. Del Poeta, S. Deaglio, G. Gaidano,
F. Tedesco, F. Malavasi, V. Gattei (Centro di Riferimento Oncologico, IRCCS, Aviano, Italy)

0070 NOVEL MOLECULAR AND CLINICAL FEATURES OF CLL EXPRESSING OR NOT EXPRESSING STEREOTYPED B CELL RECEPTORS: RESULTS OF AN ITALIAN MULTICENTRIC STUDY
R. Bomben, M. Dal-Bo, D. Capello, F. Forconi, A. Zucchetto, R. Maffei,
L. Laurenti, F. Bertoni, P. Bulian, D. Rossi, M.I. Del-Principe, F. Ilariucci,
E. Sozzi, E. Zucca, D. Degan, F. Lauria, G. Del-Poeta, D.G. Efremov,
R. Marasca, G. Gaidano, V. Gattei (Centro di Riferimento Oncologico IRCCS, Aviano, Italy)

0071 HOW DOES MBL RELATE TO CLL PATHOGENESIS? A PERSPECTIVE FROM THE IMMUNOGLOBULIN GENE REPERTOIRE ANALYSIS

1. Ghia, A. Dagklis, C. Fazi, V. Cantarelli, D. Toniolo, R. Massacane,
2. Stamatopoulos, F. Caligaris-Cappio (Università Vita-Salute San Raffaele, Milano, Italy)

0072 HS1 PROTEIN REVEALS ITS ROLE IN NORMAL AND LEUKEMIC B CELLS MIGRATION
C. Scielzo, M.T.S. Bertilaccio, M. Muzio, M. Frenquelli, B. Apollonio,
A. Dagklis, G. Simonetti, C. Fazi, P. Ghia, F. Caligaris-Cappio (Università Vita-Salute, Milano, Italy)

0073 CLL TRANSFORMING TO RICHTER’S SYNDROME CARRY STEROTYPED HCDR3S AT VERY HIGH FREQUENCY (>50%) AND DISPLAY BIASED USAGE OF HOMOLOGOUS IGHV4-39 GENES
S. Valeria, D. Capello, R. Bomben, F. Forconi, L. Laurenti, G. Del Poeta,
R. Marasca, S. Pileri, A. Carbone, M. Paulli, F. Bertoni, G. Gaidano,
V.S. Gattei, D. Rossi (Amedeo Avogadro University, Novara, Italy)

0074 THE METABOLISM OF MEVALONATE AS A SIGNALING PATHWAY INFLUENCING TUMOR-HOST INTERACTIONS AND DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
M. Coscia, S. Peola, G. Matta, F. Pantaleoni, M. Foglietta, C. Vitale,
D. Angelini, S. Chiaretti, C. Riganti, A. Guarini, D. Drandi, M. Ladetto,
A. Bosia, R. Foà, L. Battistini, M. Boccadoro, J.J. Fournie, M. Massaia (Department of Medicine and Experimental Oncology, Section of Hematology, Torino, Italy)

0075 THE PROLIFERATIVE RESPONSE TO CPG-ODN STIMULATION PREDICTS DISEASE PROGRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
L. Laurenti, M. Tarnani, I. Innocenti, P.G. Longo, S. De Matteis,
P. Chiusolo, A. Mannocci, S. Sica, G. Leone, D.G. Efremov (Policlinico A. Gemelli, Roma, Italy)

0076 UDP-GLUCURONOSYLTRANSFERASE 2B17 GENE EXPRESSION IS A NOVEL MARKER FOR PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

1. Gruber, M. Bilban, D. Heintel, H. Esterbauer, C. Fonatsch,
2. Mannhalter, K. Eigenberger, A. Gaiger, C. Skrabs, E. Porpaczy,

1. Le, A. Hauswirth, S. Stilgenbauer, U. Kroemer, K. Vanura,
2. Jaeger (Medical University of Vienna, Vienna, Austria)

0077 ALTERNATIVELY SPLICED TRANSCRIPTS OF ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) IN CHRONIC LYMPHOCYTIC LEUKEMIA. CORRELATION WITH IGHV GENE MUTATIONAL STATUS AND SURFACE IMMUNOGLOBULIN ISOTYPE EXPRESSION
F. Marantidou, M. Chatzouli, I. Athanasiadou, V. Taxynopoulou,
A. Agathagelidis, K. Valianatou, E. Kostarelli, A. Saetta, N. Stavroyianni,
E. Manioudaki, P. Korkolopoulou, N. Laoutaris, A. Anagnostopoulos,
K. Stamatopoulos, C. Belessi, E. Patsouris (General Hospital of Nikea, Piraeus, Greece)

0078 REGULATION OF CXCR4 EXPRESSION BY VEGF AND SEMA3A IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA
B.P. Power, P.M. Murphy, J.H. Harmey, P.T. Thornton (Royal College of Surgeons Ireland, Dublin, Ireland)

0079 ABERRANT GENE EXPRESSION PATTERN OF ANGIOGENESIS­RELATED FACTORS CHARACTERIZES B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
R. Maffei, S. Martinelli, I. Castelli, R. Santachiara, P. Zucchini,
M. Fontana, S. Fiorcari, G. Bonacorsi, R. Marasca, G. Torelli (University of Modena and Reggio Emilia, Modena, Italy)

0080 A PROTEOMIC APPROACH TO INVESTIGATE TARGETS ASSOCIATED WITH B-CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKAEMIA
L. Eagle, L. Cawkwell, D. Allsup (University of Hull, Hull, United Kingdom)

0081 CLL WITH T(14;18) : A DISTINCT DISEASE?

1. Put, P. Meeus, B. Chatelain, M. Stul, N. Boeckx, C. Graux,
2. Bries, C. Doyen, C. Dubois, S. Marichal, P. Pierre, A. Van Hoof,
3. Verschuere, L. Harlet, I. Wlodarska, P. Vandenberghe, L. Michaux (UZ Leuven / KULeuven, Leuven, Belgium)

0082 ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CASES WITH STEREOTYPIC IMMUNOGLOBULIN’S RECEPTORS IN UKRAINIAN COHORT
N. Bilous, I. Abramenko, A. Chumak (Research Centre for Radiation Medicine, Kiev, Ukraine)

0083 CD200 AS A TOOL FOR DIFFERENTIAL DIAGNOSIS BETWEEN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA

1. Palumbo, G. Fargione, N. Parrinello, K. Cardillo, A. Chiarenza,
2. Berretta, C. Conticello, L. Villari, F. Di Raimondo (University of Catania, Catania, Italy)

---

CHRONIC LYMPHOCYTIC LEUKEMIA - CLINICAL

0084 COMBINED THALIDOMIDE AND FLUDARABINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA RESULTS IN DISTINCT MOLECULAR AND ANTILEUKEMIC EFFECTS
K. Giannopoulos, K. Giannopoulos, A. Dmoszynska, M. Kowal,

1. Wasik-Szczepanek, P. Wlasiuk, A. Bojarska-Junak, J. Rolinski,
2. Stilgenbauer, L. Bullinger (Medical University of Lublin, Lublin, Poland)

0085 RITUXIMAB CONSOLIDATION AND MAINTENANCE THERAPY PROLONG RESPONSE DURATION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
G. Del Poeta, M.I. Del Principe, A. Siniscalchi, L. Maurillo, F. Buccisano,
A. Venditti, F. Luciano, P. Niscola, A. Zucchetto, V. Gattei, A.P. Perrotti,
P. De Fabritiis, S. Amadori (Department of Hematology, University Tor Vergata, Roma, Italy)

0086 FLUDARABINE PLUS THALIDOMIDE AS FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S. Ailawadhi, K.C. Miller, D. Depaolo, A. Whitworth, W. Brady,
M. Czuczman, Z.P. Bernstein, F. Hernandez-Ilizaliturri, S. Padmanabhan, A. Chanan-Khan (Roswell Park Cancer Institute, Buffalo, USA)

0087 LUMILIXIMAB IN COMBINATION WITH FCR FOR THE TREATMENT OF RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS FROM A PHASE I/II MULTICENTER STUDY
J. Byrd, J. Castro, I. Flinn, A. Forero-Torres, T. Kipps, N. Heerema,
Y. Kasamon, W. Wierda, T. Lin, H. Mu, S. Tangri, S. O'Brien (The Ohio State University Comprehensive Cancer Center, Columbus, USA)

0088 IDENTIFICATION OF AN IN VIVO MOLECULAR SIGNATURE OF SENSITIVITY VS RESISTANCE TO FLUDARABINE IN B CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
E. Moussay, V. El Khoury, N. Aouali, K. Van Moer, B. Leners,
F. Bernardin, A. Muller, P. Nazarov, M. Yatskou, L. Vallar, V. Palissot,
G. Berchem (CRP-Santé, Luxembourg, Luxembourg)

0089 ABNORMAL SERUM FREE LIGHT CHAIN RATIOS IN CHRONIC LYMPHOCYTIC LEUKAEMIA ARE SIGNIFICANTLY ASSOCIATED WITH EARLIER DISEASE-SPECIFIC DEATH

1. Harding, G. Pratt, R. Holder, C. Fegan, C. Pepper, D. Oscier,
2. Mead (The Binding Site, Birmingham, United Kingdom)

0090 RAI AND BINET CLASSIFICATIONS FOR CHRONIC LYMPHOCYTIC LEUKEMIA SHOULD RECOGNIZE A ROLE FOR IMMUNE THROMBOCYTOPENIA, BUT NOT FOR AUTOIMMUNE HAEMOLYTIC ANEMIA
C. Visco, I. Giaretta, M. Ruggeri, E. Novella, E. Albiero, E. Pacquola,
C. Borghero, F. Rodeghiero (Ospedale S Bortolo, Vicenza, Italy)

0091 COMPARISON OF CLADRIBINE PLUS CYCLOPHSOPHAMIDE OR FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN DIFFERENT AGE GROUPS IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (PALG-CLL3 STUDY)
T. Robak, J.Z. Blonski, J. Gora-Tybor, K. Jamroziak, L. Konopka,
B. Ceglarek, M. Calbecka, A. Kostyra, B. Stella-Holowiecka, J. Kloczko,
K. Warzocha, I. Seferynska, A. Dmoszynska, M. Kowal, K. Lewandowski,
J. Dwilewicz-Trojaczek, E. Wiater, K. Kuliczkowski, S. Potoczek,
A. Hellmann, A. Mital, A. Skotnicki, W. Nowak, K. Sulek, A. Zdunczyk,
J. Dybowicz, K. Zawilska (Med Univ of Lodz, Lodz, Poland)

0092 INCREASED SERUM BAFF (B-CELL ACTIVATING FACTOR OF THE TNF FAMILY) LEVEL IS A PECULIAR FEATURE ASSOCIATED WITH FAMILIAL CHRONIC LYMPHOCYTIC LEUKEMIA.
S. Molica, G. Digiesi, F. Mauro, R. Mirabelli, G. Cutrona, G. Vitelli,
F. Iuliano, F. Morabito, R. Foà, M. Ferrarini (Azienda ospedaliera Pugliese-Ciaccio, Catanzaro, Italy)

0093 LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
F. Forconi, A. Fabbri, M. Lenoci, E. Sozzi, M. Bocchia, A. Gozzetti,
M. Tassi, D. Raspadori, F. Lauria (University of Siena, Siena, Italy)

0094 ORAL FLUDARABINE PLUS RITUXIMAB RESULT IN HIGH COMPLETE REMISSION RATE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
G. Del Poeta, M.I. Del Principe, L. Maurillo, A. Siniscalchi, F. Buccisano,
A. Coletta, P. Bulian, A. Venditti, P. Niscola, V. Gattei, C. Simotti,
A.P. Perrotti, P. De Fabritiis, S. Amadori (Department of Hematology, University Tor Vergata, Roma, Italy)

0095 RETROSPECTIVE COMPARISION OF EFFICASY AND TOXICITY OF FC AND FCR REGIMENS IN UNTREATED PATIENTS WITH B –CELL CHRONIC LYMPHOCYTIC LEUKEMIA
A. Nikitin, A. Stadnik, N. Salogub, Yu. Lorie, N. Tsyba, A. Alexeeva,
N. Mashuk, V. Biderman, A. Zaritsky (Hematology Research Center of Russia, Moscow, Russian Federation)

0096 CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUMAB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE
S. Galimberti, N. Cecconi, G. Cervetti, G. Buda, E. Orciuolo,
F. Papineschi, F. Caracciolo, E. Benedetti, M. Petrini (Hematology, Pisa, Italy)

0097 DEMOGRAPHICS AND SURVIVAL OF PATIENTS WITH STAGE 0 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-0) AND MONOCLONAL B CELL LYMPHOCYTOSIS WITH CLL-PHENOTYPE (MBL) IN A SINGLE CENTRE 1992-2007: EFFECT OF PROPOSED NEW DIAGNOSTIC CRITERIA
A. Yong, G. White, J. Stanley, D. Buhrkuhl, J. Phillips (Otago University, Wellington, New Zealand)

0098 HCNT1 EXPRESSION AND PURINE ANALOGUE ACTIVITY: PHARMACOGENOMIC AND CLINICAL RESULTS IN CLL/SLL PATIENTS TREATED WITH 2-CDA AND RITUXIMAB
P. Bertazzoni, C. Rabascio, D. Laszlo, L. Calabrese, D. Radice,
L. Orlando, L. Preda, P. Rafaniello, F. Gigli, S. Bassi, L. Nassi,
G. Martinelli (European Institute of Oncology, Milan, Italy)

---

CHRONIC MYELOID LEUKEMIA - BIOLOGY

0099 BCR/ABL ONCOGENIC KINASE INHIBITS MISMATCH REPAIR TO PROTECT FROM APOPTOSIS AND INDUCE POINT MUTATIONS

1. Stoklosa, T. Poplawski, M. Koptyra, M. Nieborowska-Skorska,
2. Basak, A. Slupianek, M. Rayevskaya, I. Seferynska, L. Herrera,
3. Blasiak, T. Skorski (The Medical University of Warsaw, Warsaw, Poland)

0100 HIGH-RESOLUTION MAPPING OF DELETIONS OF CHROMOSOME 9Q+ IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA BY SNP-ARRAYS: WHICH GENES MATTER?
S. Colarossi, A. Gnani, S. Soverini, F. Castagnetti, G. Marzocchi,
S. Luatti, A. Astolfi, S. Formica, I. Iacobucci, E. Ottaviani, F. Palandri,
A. Poerio, M. Amabile, G. Rosti, A. Pession, N. Testoni, M. Baccarani,
G. Martinelli (Institute of Hematology and Medical Oncology "Seràgnoli", Bologna, Italy)

0101 PHILADELPHIA –POSITIVE LEUKAMIA PATIENTS ALREADY HARBOURING ABL KINASE DOMAIN MUTATIONS HAVE A HIGHER LIKELIHOOD OF DEVELOPING FURTHER MUTATIONS UNDER THE SELECTIVE PRESSURE OF NOVEL TYROSINE KINASE INHIBITORS
S. Soverini, A. Gnani, S. Colarossi, F. Castagnetti, F. Palandri, S. Paolini,
E. Abruzzese, S. Merante, M. Rondoni, I. Iacobucci, A. Poerio, M. Amabile,
C. Papayannidis, P. Giannoulia, G. Rosti, M. Baccarani, G. Martinelli (Institute of Hematology and Medical Oncology "L.e A. Seràgnoli", Bologna, Italy)

0102 P210-DERIVED PEPTIDE VACCINATIONS IN CML PATIENTS INDUCE “NOT REGULATORY” CD4+/ CD25HIGH+/FOXP3+ AND CD4+/PERFORIN+ PEPTIDE-SPECIFIC T CELLS
M.B. Bocchia, M. Ippoliti, M. Tassi, E. Abruzzese, M. Defina,
M.M. Trawinska, A. Gozzetti, D. Raspadori, R. Crupi, F. Lauria (University of Siena, Siena, Italy)

0103 PATIENT-SPECIFIC IC50 ASSAYS IN IMATINIB-RESISTANT CML PATIENTS ARE HIGHLY VARIABLE AND MAY BE CLINICALLY RELEVANT
D. White, V. Saunders, S. Quinn, T. Hughes (IMVS and Hanson Institute, Adelaide, Australia)

0104 PHILADELPHIA CHROMOSOME POSITIVE (PH+) LEUKEMIA CELLS ARE NOT ENRICHED IN THE PRIMITIVE (CD34+CD38-) STEM CELL FRACTION DURING TYROSINE KINASE INHIBITOR THERAPY
S. Mustjoki, P. Rohon, K. Rapakko, S. Hernesniemi, P. Koskenvesa,
T. Lundan, K. Porkka (Hematology Research Unit, Helsinki, Finland)

0105 FOXO TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING
F. Messa, C. Panuzzo, F. Arruga, P. Nicoli, E. Messa, A. Morotti, A. Rotolo,
S. Carturan, T. Kalebic, I. Iacobucci, G. Martinelli, E. Bracco, G. Saglio,
D. Cilloni (University of Turin, Turin, Italy)

0106 DOWN-REGULATION OF PROTEIN TYROSINE PHOSPHATASE GAMMA (PTPRG) IN CHRONIC MYELOID LEUKEMIA (CML)
M. Della Peruta, M. Martinelli, M. Monne, D. Pintani, T. Grafone,
I. Iacobucci, M. Murineddu, F. Vinante, C. Tecchio, M. Vezzalini, G. Piras,
A. Gabbas, A. Mafficini, C. Sorio (University of Verona, Verona, Italy)

0107 ABL KINASE DOMAIN MUTATIONS ARE INFREQUENT IN EARLY-CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
S. Soverini, A. Gnani, S. Colarossi, F. Castagnetti, F. Palandri,
E. Abruzzese, E. Orlandi, M. Breccia, G. Specchia, F. Gherlinzoni,
A. Poerio, M. Amabile, I. Iacobucci, G. Rosti, M. Baccarani, G. Martinelli (Institute of Hematology and Medical Oncology "L.e A. Seràgnoli", Bologna, Italy)

0108 THE EFFECT OF IMATINIB MESYLATE ON THE SIGNAL TRANSDUCTION CASCADE REGULATING TELOMERASE ACTIVITY IN K562 CELLS AND IN K562 CELLS RESISTANT TO IMATINIB MESYLATE
R. Mor, O. Uziel, O. Shpilberg, J. Lahav, P. Raanani, E. Rabizadeh,
Y. Zimra, M. Lahav, G. Granot (Felsenstein Medical Research Center, Petah-tikva, Israel)

0109 DYNAMICS OF MUTANT BCR-ABL POSITIVE CLONES AFTER CESSATION OF IMATINIB TREATMENT
B. Hanfstein, M.C. Mueller, S. Kreil, T. Schenk, C. Lorentz, U. Schwindel,
A. Leitner, R. Hehlmann, A. Hochhaus (Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany)

0110 GENE EXPRESSION DOWNREGULATION BY HAPLOINSUFFICIENCY MECHANISM IN CHRONIC MYELOID LEUKEMIA WITH DELETIONS ON DER(9)
F. Albano, A. Zagaria, L. Anelli, A. Pannunzio, A. Russo Rossi,
F. Manodoro, N. Coccaro, V. Liso, M. Rocchi, G. Specchia (Hematology-University of Bari, Bari, Italy)

0111 EVIDENCE THAT PPAR ACTIVATION MAY CONTROL THE EXPRESSION OF THE IMATINIB TRANSPORTER HOCT1 IN CHRONIC MYELOID LEUKAEMIA
L. Wang, M. Austin, E. Clark (Department of Haematology, Liverpool, United Kingdom)

0112 EFFECT OF TYROSINE KINASE INHIBITORS ON REGULATORY T-CELLS (TREGS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
P. Rohon, K. Porkka, S. Mustjoki (Hematology Research Unit, Biomedicum, Helsinki University Central Hospital (HUCH, Helsinki, Finland)

0113 OMACETAXINE INDUCES THE RAPID LOSS OF MCL-1 BUT NOT OTHER ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS IN BCR-ABL POSITIVE CELLS
H. Segal, S. Michaels, D. Brown (Deakin University, Geelong, Australia)

0114 ROLE OF IMATINIB MESYLATE IN OSTEOBLASTOGENESIS
D. Tibullo, C. Giallongo, P. La Cava, S. Berretta, F. Stagno,
A. Chiarenza, C. Conticello, G. Palumbo, F. Di Raimondo (Division of Hematology, University of Catania, Catania, Italy)

0115 NCK BETA ADAPTER COORDINATES BCR-ABL/SAM68 INTERMOLECULAR INTERACTION
E. Bracco, E. Bracco, E. Deklic, V. Rosso, S. Mussino, F. Arruga,
R. Catalano, S. Carturan, F. Messa, I. Defilippi, C. Panuzzo, P. Nicoli,
E. Messa, A. Rotolo, R. Pedrola, D. Cilloni, G. Saglio (University, Orbassano, Italy)

0116 UNUSUAL SINGLE BAC COPY NUMBER CHANGES IN CHRONIC MYELOID LEUKEMIA: EXAMPLES FROM CELL LINES AND PATIENTS
A. Chanalaris, A. Chanalaris, D. Brazma, M. Valgañón, C. Grace,
E.P. Nacheva (Royal Free & UC Medical School, London, United Kingdom)

---

CHRONIC MYELOID LEUKEMIA - CLINICAL I

0117 NILOTINIB IN CHRONIC MYELOGENOUS LEUKAEMIA IN BLAST CRISIS (CML-BC) PATIENTS WITH IMATINIB-RESISTANCE OR ­INTOLERANCE: UPDATED PHASE 2 RESULTS
J. Giles, R.A. Larson, H.M. Kantarjian, P. Le Coutre, F. Palandrini,
A. Haque, N. Gallagher, O.G. Ottmann (CTRC at the UT Health Science Center San Antonio, San Antonio, USA)

0118 NILOTINIB IN IMATINIB-RESISTANT OR –INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE (CML-AP): UPDATE OF A PHASE 2 STUDY
P. le Coutre, A. Hochhaus, J. Apperley, G. Ossenkoppele, A. Haque,
N. Gallagher, M. Baccarani, J. Cortes, H.M. Kantarjian (Charité, Berlin, Germany)

0119 DASATINIB IS ASSOCIATED WITH DURABLE TREATMENT RESPONSES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: LONG-TERM FOLLOW-UP FROM THE PHASE I TRIAL (CA180002)
J. Cortes, C.L. Sawyers, H.M. Kantarjian, N.P. Shah, R. Paquette,
E. Bleickardt, P. Paliwal, M. Talpaz (MD Anderson Cancer Center, Houston, United States of America)

0120 INTERIM RESULTS FROM A PHASE I CLINICAL TRIAL OF THE BCR-ABL INHIBITOR XL228 IN DRUG-RESISTANT PH+ LEUKEMIAS
P. Shah, E. Asatiani, J. Cortes, R. L. Paquette, J. Pinilla-Ibarz, C. Kasap,
L. A. Bui, Y. Yaron, D.O. Clary, M. Talpaz (UCSF, San Francisco, USA)

0121 EFFICACY OF NILOTINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EARLY CHRONIC PHASE (CML-CP)
J. Cortes, D. Jones, S. O'Brien, A. Ferrajoli, G. Borhtakur, J. Burger,
W. Wierda, G. Garcia-Manero, L. Letvak, H. Kantarjian (MD Anderson Cancer Center, Houston, United States of America)

0122 DASATINIB COMPARED WITH HIGH-DOSE IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER FAILURE OF STANDARD-DOSE IMATINIB – A TWO-YEAR UPDATE OF THE START-R STUDY
P. Rousselot, S. Corm, R. Paquette, E. Bleickardt, D. Dejardin,
H.M. Kantarjian, D. Niederwieser (Hôpital Mignot, Versailles, France)

0123 DATA FROM A MULTICENTER OPEN LABEL STUDY OF SUBCUTANEOUS (SC) OMACETAXINE MEPESUCCINATE (OMA) IN IMATINIB (IM)-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) WITH THE T315I MUTATION
J. Cortes, H.J. Khoury, S. Corm, F.E. Nicolini, A.C. Benichou,
A.R. Craig, E. Humphriss, H. Kantarjian (MD Anderson Cancer Center, Houston, United States of America)

0124 CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS TREATED WITH IMATINIB 600 MG: OUTCOME OF THE PATIENTS ALIVE AFTER A 6-YEAR FOLLOW-UP
F. Palandri, F. Castagnetti, N. Testoni, S. Bassi, M. Breccia, R. Varaldo,
A. Liberati, G. Specchia, E. Zuffa, G. Rege-Cambrin, M. Bocchia,
G. Saglio, F. Pane, G. Martinelli, M. Baccarani, G. Rosti (Department of Hematology "Seragnoli", Bologna, Italy)

0125 IMATINIB 600 MG ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP
F. Palandri, F. Castagnetti, N. Testoni, G. Alimena, G. Rege-Cambrin,
M. Breccia, G. Specchia, B. Bruno, M. Miglino, F. Levato, G. Saglio,
F. Pane, G. Martinelli, M. Baccarani, G. Rosti (Department of Hematology "Seragnoli", Bologna, Italy)

0126 USE OF IMATINIB IN CHRONIC PHASE CML IN CLINICAL PRACTICE: THE UNIC STUDY

1. Steegmann, M. Michallet, E. Morra, D. Marin, G. Ossenkoppele,
2. Verhoef, T. Kühr, M. Björeman, L. Van Bree, K. Cerri (Hospital de La Princesa, Madrid, Spain)

0127 EXPRESSION OF H-OCT1 PREDICTS FOR ACHIEVEMENT OF CCYR IN IMATINIB TREATED PATIENTS WHILE THE LEVEL OF PHOSPHO-CRKL INHIBITION IN CD34 POSITIVE CELLS SEEMS TO BE OF LITTLE PROGNOSTIC VALUE
S. Sorouri Khorashad, S. Wagner, D. Marin, A.G. Reid, D. Milojkovic,
S. Willimott, G. Gerrard, L. Foroni, J.M. Goldman, J.F. Apperley (Imperial College of London, London, United Kingdom)

0128 DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB

1. A RETROSPECTIVE SAFETY ANALYSIS
2. Guilhot, S.L. Goldberg, R.M. Stone, M. Mauro, Y. Matloub, T.T. Chen,

H.J. Khoury (CHU de Poitiers, Poitiers, France)
0129 HAPLOIDENTICAL BLOOD AND MARROW TRANSPLANTATION IN ADVANCED CHRONIC MYELOID LEUKEMIA: A SINGLE-CENTER REPORT OF 35 PATIENTS
Z. Zhao, T. Wu, J.B. Wang, X.Y. Cao, Y.M. Ying, D.P. Lu (Beijing Daopei Hospital, Beijing, China)

0130 BLASTS, EOSINOPHILS, SPLEEN ENLARGEMENT, AND CONCOMITANT DISEASE PROVIDE INDEPENDENT SIGNIFICANT PROGNOSTIC INFORMATION ON THE PROBABILTY TO LIVE MORE THAN NINE YEARS WITH CONSERVATIVE DRUG TREATMENT
M. Pfirrmann, F. Waibel, M. Lauseker, S. Saussele, M. Rohrbacher,
A. Leitner, J. Hasford, R. Hehlmann, A. Hochhaus (Ludwig­Maximilians-University, Munich, Germany)

0131 MEASUREMENT OF IMATINIB AND ITS METABOLITE, CGP-74588, IN TREATED CHRONIC MYELOID LEUKAEMIA PATEINTS BY HPLC
A. Davies, A. Hayes, K. Knight, S.J. Watmough, M. Pirmohamed,
R.E. Clark (University of Liverpool, Liverpool, United Kingdom)

0132 COMBINED THERAPY WITH IMATINIB FOR INDUCTION AND INTERFERON AS CONSOLIDATION INDUCES A SUSTAINED CYTOGENETIC REMISSION THAT FACILITATES DISCONTINUATION OF ANTI LEUKEMIC THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA
I. Hardan, N. Amariglio, L. Trachtenbrot, A. Simon, A. Shimoni, I. Levi,
M. Koren- Michowitz, Y. Binenbaum, G. Rechavi, A. Nagler (Sheba Medical Center, Tel Hashomer-, Israel)

0133 TREATMENT OF PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB: INTRODUCING THE CONCEPT OF STABLE MOLECULAR RESPONSE
F. Palandri, I. Iacobucci, S. Soverini, F. Castagnetti, A. Poerio, N. Testoni,
G. Alimena, M. Breccia, G. Rege-Cambrin, M. Tiribelli, R. Varaldo,
E. Abruzzese, B. Bruno, F. Pane, G. Saglio, G. Martinelli, M. Baccarani,
G. Rosti (Department of Hematology "Seragnoli", Bologna, Italy)

0134 EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS
F. Nicolini, G. Alimena, Z. Shen, H.-K. Al-Ali, A. Turkina, G. Smith,
R. Pasquini, S. Jootar, Y. Hsu, M.L. Veronese, B. Powell (Hôpital Edouard Herriot, Lyon, France)

---

CHRONIC MYELOID LEUKEMIA AND MYELOPROLIFERATIVE DISORDERS

0135 DEVELOPMENT OF PROTOTYPE REFERENCE MATERIALS FOR BCR-ABL QUANTITATIVE RT-PCR
C.P. Cross, A. Hochhaus, M.C. Mueller, G. Saglio, S. Branford,
T.P. Hughes, J. Gabert, Y.L. Wang, P. Metcalfe, H.E. White (University of Southampton, Salisbury, United Kingdom)

0136 DASATINIB EARLY INTERVENTION AT CYTOGENETIC RATHER THAN HEMATOLOGIC RESISTANCE TO IMATINIB IS ASSOCIATED WITH MORE FAVORABLE RESPONSES
H. Kantarjian, A. Quintas-Cardama, S. O'Brien, F. Ravandi,
G. Borthakur, Y. Matloub, D. Liu, T.T. Chen, J. Cortes (MD Anderson Cancer Center, Houston, United States of America)

0137 RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE
J. Radich, D.-W. Kim, G. Martinelli, S. Soverini, S. Branford,
M. Mueller, A. Haque, Y. Shou, A. Hochhaus, T. Hughes, G. Saglio (Fred Hutchinson Cancer Research Center, Seattle, USA)

0138 EPIDEMIOLOGICAL STUDY ON SURVIVAL OF CHRONIC MYELOID LEUKEMIA (CML) AND DE NOVO PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS WITH T315I MUTATION - A PRELIMINARY ANALYSIS

1. Kim, W. Zhou, G. Martinelli, C. Chuah, F. Yagasaki, I. Dufva, S. Peter,
2. Mauro, F. Giles, J. Cortes, J. Pearson, J. Goldman, F. Nicolini (St. Mary's Hospital, The Catholic University of Korea, Seoul, South-Korea)

0139 EFFICACY OF SUBCUTANEOUS HOMOHARRINGTONINE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS (TKI) AND HARBORING A BCR-ABL MUTATION
D. Marin, F. Maloisel, L. Legros, F.E. Nicolini, L. Roy, P. Rousselot (Imperial College London, London, United Kingdom)

0140 SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN THE ABL KINASE DOMAIN OF CML PATIENTS – PITFALLS IN THE DETECTION OF RELEVANT BCR-ABL MUTATIONS
T. Ernst, M.C. Müller, J. Hoffmann, P. Erben, B. Hanfstein, A. Leitner,
R. Hehlmann, A. Hochhaus (Wessex Regional Genetics Laboratory, Salisbury, United Kingdom)

0141 MINIMAL CROSS-INTOLERANCE BETWEEN NILOTINIB AND IMATINIB IN PATIENTS WITH IMATINIB-INTOLERANT CHRONIC MYELOGENOUS LEUKAEMIA (CML) IN CHRONIC PHASE (CP) OR ACCELERATED PHASE (AP)
A. Hochhaus, H.M. Kantarjian, M. Baccarani, P. Le Coutre, A. Haque,
N. Gallagher, J. Cortes, F. Giles (MedicalFakultät Mannheim der Universität Heidelberg, Mannheim, Germany)

0142 A NEW ASSOCIATION BEETWEN THE ALLELIC JAK2V617F BOURDEN AND THE PLATELET VOLUME IN POLYCYTEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)
M. Sobas, M. Pérez-Encinas, C. Quinteiro, T. González, E. Ansoar,
S. Ordoñez, J.L. Bello (Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, Spain)

0143 DECISIONAL FLOW WITH A SCORE SYSTEM TO START PLATELET-LOWERING TREATMENT IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET): LONG-TERM RESULTS
R. Latagliata, A. Rago, A. Spadea, C. Santoro, I. Carmosino, M. Breccia,
L. Napoleone, A. Fama, F. Biondo, P. Volpicelli, M.C. Petti, G. Alimena,
M.G. Mazzucconi (Hematology- University "La Sapienza", Rome, Italy)

0144 JAK2 MUTATION AND AN ADDITIONAL THROMBOPHILIC STATE ARE MAJOR PROTHROMBOTIC RISK FACTORS IN MYELOPROLIFERATIONS WITH THROMBOCYTHEMIA – DATA FROM A REGISTRY OF ANAGRELIDE-TREATED PATIENTS
J. Schwarz, M. Penka, M. Doubek, Y. Brychtova, O. Cerna, P. Dulicek,
J. Kissova, T. Pavlik (Institute of Hematology and Blood Transf, Prague, Czech Republic)

0145 ABSENCE OF THE JAK2 EXON 12 MUTATIONS IN PATIENTS WITH SPLANCHNIC VENOUS THROMBOSIS AND WITHOUT OVERT CHRONIC MYELOPROLIFERATIVE DISORDERS
A. Fiorini, E. Rossi, T. Za, A. Ciminello, P. Chiusolo, S. Sica, G. Leone,
V. De Stefano (Institute of Hematology, Catholic University, Rome, Italy)

0146 BLOOD P50 EVALUATION ENHANCES DIAGNOSTIC DEFINITION OF ISOLATED ERYTHROCYTOSIS
E. Rumi, F. Passamonti, L. Pagano, M. Ammirabile, L. Arcaini, C. Elena,
A. Flagiello, R. Tedesco, C. Vercellati, A.P. Marcello, D. Pietra, R. Moratti,
M. Cazzola, M. Lazzarino (Department of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy)

0147 TREATMENT RESPONSE AND COMPLICATIONS OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA RECEIVING HYDROXYUREA
D. Sotiropoulos, A. Papalexandri, P. Tsirigotis, A. Pouli,
P. Kyriazopoulos, M. Protopapa, I. Dervenoulas, A. Fassas,
A. Anagnostopoulos (G Papanikolaou Hospital, Thessaloniki, Greece)

0148 OCCULT T-CELL CLONES OCCUR IN THE MAJORITY OF PATIENTS WITH SUSTAINED AND UNEXPLAINED HYPEREOSINOPHILIA
G. Helbig, M. Majewski, J. Grzegorczyk, J. Dziaczkowska, B. Stella-Holowiecka, J. Wojnar, S. Krzemien (Silesian Medical University, Katowice, Poland)

0149 LOW DOSE SPLENIC IRRADIATION IN MYELOFIBROSIS: OUTCOMES AND TOXICITY OF THREE RADIATION SCHEDULE
M. Federico, P. Guerrieri, A. Russo, G. Cardinale, A. Giordano, R. Lagalla,
P. Montemaggi, G. Pagnucco (University of Palermo, Palermo, Italy)

0150 POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: JAK2V617F MUTATION IS MORE COMMON IN OLDER PATIENTS
M.L. Randi, E. Ruzzon, M. Scapin, F. Tezza, I. Bertozzi, F. Fabris (University of Padua, Padua, Italy)

0151 UNUSUAL VEIN THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)
M.L. Randi, M. Scapin, F. Tezza, N. Candeo, I. Bertozzi, E. Duner (University of Padua, Padua, Italy)

0152 A TIME AND DOSE TO RESPONSE STUDY OF IMATINIB THERAPY FOR CHRONIC HYPEREOSINOPHILIC SYNDROMES
T. Intermesoli, F. Delaini, S. Salmoiraghi, S. Acerboni, V. Guerini,
A. Vannucchi, S. Mappa, G. Rossi, V. Rossi, E. Di Bona, A. Carobbio,
T. Barbui, A. Rambaldi, R. Bassan (Ospedali Riuniti di Bergamo, Bergamo, Italy)

---

CYTOGENETICS AND MOLECULAR DIAGNOSTICS I

0153 EUROPEAN STANDARDIZATION OF BCR-ABL MRNA QUANTIFICATION

1. Müller, P. Erben, G. Saglio, S. Branford, B. Hanfstein, D. Gosenca,
2. Ernst, R. Hehlmann, N.C.P. Cross, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)

0154 RESCUE OF GENOMIC INFORMATION IN 72% OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WITH NORMAL/FAILED CYTOGENETICS AND IDENTIFICATION OF NF1 DELETION AS THE HALLMARK OF A SUBSET OF NOTCH1-MUTATED T-ALL. A GIMEMA STUDY
C. Matteucci, G. Barba, E. Varasano, A. Vitale, L. Elia, M. Mancini,
V. Pierini, R. La Starza, B. Crescenzi, S. Romoli, V. Nofrini, M.F. Martelli,
R. Foà, C. Mecucci (Hematology, IBiT Foundation, University of Perugia, Perugia, Italy)

0155 CONSTITUTIVE ACTIVATION OF PDGFRA OR PDGFRB BY DIVERSE FUSION GENES CAN RAPIDLY BE DETECTED BY QUANTITATIVE RT-PCR
P. Erben, M.C. Mueller, D. Gosenca, G. Metzgeroth, H. Popp, C. Walz,
E. Thomas, R. Hehlmann, N. Cross, A. Hochhaus, A. Reiter (University Hospital Mannheim, Mannheim, Germany)

0156 MUTATIONS OF THE WT1 TRANSCRIPTION FACTOR ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL-AN ANALYSIS IN 368 AML PATIENTS WITH NORML KARYOTYPE <60 YEARS TREATED IN THE AML96 PROTOCOL OF THE DSIL
C. Thiede, T. Illmer, S. Soucek, M. Schaich, G. Ehninger (University Hospital Carl Gustav Carus, Dresden, Germany)

0157 MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) IS A POWERFUL TECHNIQUE TO IDENTIFY PROGNOSTIC RELEVANT CHROMOSOMAL DELETIONS AND DUPLICATIONS IN CLL PATIENTS M.-J.P.L. Stevens-Kroef, A. Simons, H. Gorissen, T. Feuth,
D. Olde Weghuis, A. Buijs, R. Raymakers, A. Geurts van Kessel (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands)

0158 PATTERN OF MENINGIOMA 1 GENE (MN1) EXPRESSION IN DIFFERENT GENETIC SUBSETS OF ACUTE AND CHRONIC MYELOID LEUKAEMIAS AND ITS POTENTIAL USE AS A MARKER FOR MINIMAL RESIDUAL DISEASE DETECTION
F. Arruga, F. Messa, E. Gottardi, M. Fava, S. Carturan, C. Panuzzo,
E. Bracco, E. Messa, P. Nicoli, A. Rotolo, I. Iacobucci, F. Lo Coco,
G. Martinelli, G. Saglio, D. Cilloni (University of Turin, Turin, Italy)

0159 INFANT ALL PATIENTS WITH T(4;11)/MLL-AF4 FUSION HAVE A DIFFERENT GENOTYPIC PROFILE THAN OLDER ALL CHILDREN
M. Bardini, R. Spinelli, L. Corral, E. Mangano, G. Fazio, I. Cifola,
A. Biondi, C. Battaglia, G. Cazzaniga (M. Tettamanti Research Center, Monza, Italy)

0160 COMBINED INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION IS A VALID TOOL FOR FULL GENOMIC INVESTIGATION AND DIAGNOSTIC SCREENING IN T-ALL. A GIMEMA STUDY
R. La Starza, P. Gorello, E. Varasano, V. Pierini, A. Guarini, A. Vitale,
A. Bardi, A. Cuneo, M.F. Martelli, R. Foà, L. Elia, C. Mecucci (Hematology, IBiT Foundation, University of Perugia, Perugia, Italy)

0161 THE COINCIDENCE OF THE JAK2V617F AND 5Q-DELETIONS IS ASSOCIATED TO VARIABLE MYELOPROLIFERATIVE AND MYELODYSPLASTIC PHENOTYPES: REPORT OF 13 CASES
U. Bacher, T. Haferlach, C. Haferlach, T. Weiss, W. Kern, S. Schnittger (University of Hamburg, Germany, Hamburg, Germany)

0162 GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
P. Nemec, Z. Zemanova, K. Michalova, J. Tajtlova, H. Greslikova,
H. Filkova, R. Zaoralova, I. Spicka, E. Gregora, D. Kralova, R. Kupska,
M. Krejci, L. Pour, L. Zahradova, V. Sandecka, Z. Adam, P. Kuglik,
R. Hajek (University Research Centre - Czech Myeloma Group, Brno, Czech Republic)

0163 GENE COPY NUMBER CHANGES IN MYELODYSPLASTIC SYNDROMES
I. Borze, E. Juvonen, E. Elonen, S. Knuutila (Haartman Institute, Helsinki, Finland)

0164 MOLECULAR CYTOGENETIC STUDY OF IMMUNOFLUORE­SCENTLY LABELED PLASMA CELLS AND PROGNOSTIC SIGNIFICANCE OF CLONAL CHROMOSOMAL ABERRATIONS IN 208 PATIENS WITH MULTIPLE MYELOMA
Z. Zemanova, K. Michalova, J. Tajtlova, L. Pavlistova, A. Oltova,
H. Filkova, P. Kuglik, P. Nemec, D. Kralova, M. Holzerova, J. Balcarkova,
M. Jarosova, J. Rabasova, M. Hruba, H. Fischlova, I. Spicka, E. Gregora,
Z. Adam, V. Scudla, V. Maisnar, M. Schutzova, R. Hajek (General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic)

0165 METHYLATION STATUS OF THE PROMOTER OF 25 TUMOUR SUPPRESSOR GENES IN CHRONIC MYELOMONOCYTIC LEUKAEMIA (CMML)
E. Such, A. Valencia, J. Cervera, M.L. Senent, I. Luna, E. Marco,
M. Mallo, F. Solé, S. Oltra, R. Collado, A. Vicente, V. Amigo,
J.C. Hernández-Boluda, E. Luño, O. Fuster, E. Barragan, P. Bolufer,
M.A. Sanz, G. Sanz (Hospital Universitario La Fe, Valencia, Spain)

0166 FISH IMPROVES THE DETECTION OF 5Q31 DELETION IN MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT CYTOGENETIC EVIDENCE OF 5Q­
M. Mallo, L. Arenillas, B. Espinet, M. Salido, J.M. Hernández,
E. Lumbreras, M. Del Rey, E. Arranz, S. Ramiro, P. Font, O. González,
M. Renedo, J. Cervera, E. Such, G.F. Sanz, E. Luño, C. Sanzo,

1. Calasanz, J. Mayans, C. García-Ballesteros, V. Amigo, R. Collado,
2. Oliver, F. Carbonell, E. Bureo, A. Insunza, L. Yañez, M.J. Muruzabal,
3. Gómez-Beltrán, R. Andreu, P. León, V. Gómez, A. Sanz, N. Casasola,
4. Moreno, A. Alegre, M.L. Martín, C. Pedro, S. Serrano, L. Florensa,
5. Solé (Hospital del Mar, Barcelona, Spain)

---

INFECTIOUS DISEASES, SUPPORTIVE CARE

0167 WHICH IS THE OPTIMAL DOSAGE OF VALGANCICLOVIR AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT?
A. Candoni, E. Simeone, M. Tiribelli, R. Fanin (Division of Hematology, Udine, Italy)

0168 VORICONAZOLE PROPHYLAXIS AMONG AUTOLOGOUS STEM CELL TRANSPLANT PATIENTS
T. Gastinne, S. Le Gouill, F. Gay-Andrieu, A. Clavert, C. Touzeau,
V. Safar, J.-L. Harousseau, P. Moreau (University Hospital of Nantes, Nantes, France)

0169 IS DOMESTIC TAP WATER A RISK FACTOR FOR INFECTIONS IN NEUTROPENIC PATIENTS?
H. von Baum, M. Bommer, A. Forke, J. Holz, P. Frenz, N. Wellinghausen (Ulm University Hospitals, Ulm, Germany)

0170 LOW MORTALITY OF INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY FOR ACUTE LEUKAEMIA: EXPERIENCE FROM A SINGLE INSTITUTION NOT USING ROUTINE ANTIFUNGAL PROPHYLAXIS
F.H. Hitz, K. Boggian (Kantonsspital St.Gallen, St.gallen, Switzerland)

0171 IS SERUM INTERLEUKIN-8 (IL-8) A USEFUL MARKER TO DISCRIMINATE LOW OR HIGH PROBABILITY OF INFECTION IN HOSPITALIZED PATIENTS WITH NEUTROPENIC FEVER?
Y.H. Tromp (University Medical Center, Groningen, The Netherlands)

0172 MATERNAL HIV INFECTION AND ITS IMPACT ON CORD BLOOD CYTOKINES AND B CELL ONTOGENY
I.G.H. Lorand-Metze, E. Borges-Almeida, M.M.S. Vilela, H. Milanez,
B.M. Abramczuk, K. Metze (State University of Campinas, Campinas, Brazil)

0173 INCIDENCE OF HUMAN HERPES VIRUS TYPE 7 (HHV-7) INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES WHOSE DISEASE COURSE IS ACCOMPANIED BY NEUTROPENIA
G. Lejniece, D. Auzina, A. Lejnieks, S. Kozireva, S. Chapenko,
M. Chistjakov, Z. Nora, M. Murovska (The National center of Hematology, Riga East Hospital, Clinic"Linezers", Riga, Latvia)

0174 IN HIGH RISK ACUTE LEUKEMIA PATIENTS EARLY ANTIFUNGAL THERAPY AND DIAGNOSTIC PROCEDURES IMPROVE THE OUTCOME OF INVASIVE MOULD INFECTIONS
A. Nosari, M. Riva, A. Volonterio, M. Montillo, L. Marbello, A. Brizio,
A. Molteni, C. Vanelli, C. Gabutti, G. Nador, E. Morra (Niguarda Cà Granda Hospital, Milan, Italy)

0175 CHANGING EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS AMONG HAEMATOLOGICAL PATIENTS: RESULTS OF 46 MONTH SURVEILLANCE STUDY
C. Cattaneo, E. Borlenghi, F. Bracchi, M.A. Capucci, M. Micheletti,
A.M. Pelizzari, A. Re, G. Rossi (Spedali Civili, Brescia, Italy)

0176 SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF BRONCHOALVEOLAR LAVAGE AS ETIOLOGICAL DIAGNOSTIC TOOL FOR PULMONARY INFILTRATES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
F. Onida, P. Usardi, C. Annaloro, M.L. Ranzi, G. Saporiti, C. Olivares,
C. Boschetti, L. Rosso, A. Maraschini, M. Colombi, A. Grancini,
A. Della Volpe, N.S. Fracchiolla, G. Lambertenghi Deliliers (Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, University of Milan, Milano, Italy)

0177 ITRACONAZOLE VERSUS AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR PERSISTENT FEVER IN NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: EVIDENCE FROM A META-ANALYSIS OF 618 PATIENTS
M. Yoshida (Teikyo University School of Medicine, Kawasaki, Japan)

0178 NEUTROPHIL VOLUME DISTRIBUTION WIDTH: A NEW AUTOMATED HEMATOLOGIC PARAMETER FOR ACUTE INFECTION

1. Papakonstantinou, A. Chondrothanasi, E. Christodoulaki,
2. Grafakos, A. Skourbouti, A. Lavda, P. Safioleas, C. Manti (Thriasion Hospital, Athens, Greece)

0179 VORICONAZOLE AS SALVAGE THERAPY IN IMMUNOCOMPROMISED PATIENTS WITH PULMONARY ASPERGILLOSIS WHO RECEIVED FIRST LINEE ANTIFUNGAL THERAPY WITH CASPOFUNGIN
E. Simeone, A. Candoni, M. Chiozzotto, R. Fanin (Division of Hematology, Udine, Italy)

0180 HOW COMPLEMENT AMPLIFICATION CAN BE STIMULATED AT THE ONSET OF A SYSTEMIC INFLAMMATORY RESPONSE IN SEPSIS

1. Lutz, S. Fumia, J.S. Goede, M. Fischler, A. Luginbühl, S. Frick,
2. Fodor (ETH Zurich, Zurich, Switzerland)

0181 HBV MARKERS IN ACUTE LEUKAEMIA PATIENTS TREATED WITH MYELOSUPPRESSIVE CHEMOTHERAPY: A MONOCENTRIC EXPERIENCE
A. Ferrari, M. Pacilli, E. Conte, E. Montefusco, M.A. Aloe Spiriti,
C. Tatarelli, R. Porrini, M. Di Fonzo, S. Angeletti, M. Marignani,
B. Monarca (Un. "La Sapienza" II facoltà Az.Osp. Sant'Andrea, Roma, Italy)

0182 HEPATITIS B VIRUS (HBV) REACTIVATION CAN OCCUR IN SPITE OF LAMIVUDINE PROPHYLAXIS IN HBV CARRIERS TREATED WITH CHEMOTHERAPY. AN ANALYSIS OF 17 CASES
M. Drera, A.M. Pelizzari, M. De Vecchi, A. Tucci, L. Bettini, M. Puoti,
G. Rossi (Spedali Civili di Brescia, Brescia, Italy)

0183 EFFECTIVE SECONDARY ANTI-FUNGAL PROPHYLAXIS WITH VORICONAZOLE
F. Dignan, V. Grigoriadou, F. Maxwell, S. Evans, A. Riddell, B. Shaw,
M. Ethell, J. Treleaven, G. Morgan, M. Potter (The Royal Marsden Hospital, Surrey, United Kingdom)

0184 THE ROLE OF BRONCHOALVEOLAR LAVAGE (BAL) IN EVALUATING NEW PULMONARY INFILTRATES ON COMPUTED TOMOGRAPHY IN HAEMATOLOGY PATIENTS WITH NEUTROPENIC FEVER UNRESPONSIVE TO BROAD-SPECTRUM ANTIBIOTICS
T. Todd, D. Enoch (Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom)

---

MULTIPLE MYELOMA - BIOLOGY

0185 BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW IS ASSOCIATED WITH POLYMORPHISMS OF THE CYTOCHROME P450 CYP2C8 IN MULTIPLE MYELOMA: A GENOME WIDE SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS
E. Sarasquete, R. Garcia-Sanz, L. Marin, M. Alcoceba, M.C. Chillon,
A. Balanzategui, C. Santamaria, J. Blade, J. De la Rubia, J. Petit,
M.T. Hernandez, J. Lahuerta, M. Gonzalez, F. San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)

0186 ARRAY CGH HIGHLIGHTS GENETIC DIFFERENCES BETWEEN MGUS AND MYELOMA
L. Chiecchio, G. Dagrada, R.K.M. Protheroe, D.M. Stockley,
G.J. Morgan, N.C.P. Cross, C.J. Harrison, F.M. Ross (University of Southampton, Salisbury, United Kingdom)

0187 BASED ON DIFFERENTIAL EXPRESSION OF ANGIOGENIC GENES ALONE, BEING POLYCLONAL PLASMABLAST (PPC), BONE MARROW PLASMA CELL (BMPC) AND MULTIPLE MYELOMA CELL (MMC) CAN BE PREDICTED, BUT BEEING EARLY STAGE/ VS. THERAPY-REQUIRING MULTIPLE MYELOMA CAN NOT
D. Hose, J. Moreaux, T. Meißner, J.-F. Rossi, A. Benner, K. Mahtouk,
A. Seckinger, C. Heiß, M. Hundemer, T. Rème, J. Hillengass, K. Herde,
U. Bertsch, J. DeVos, S. Wenisch, V. Pantesco, A. Jauch, E. Jourdan,
H. Goldschmidt, B. Klein, T. Möhler (Universitätsklinikum Heidelberg, Heidelberg, Germany)

0188 BONE MICROENVIRONMENT CELLS REVEALS A DIFFERENT GENE EXPRESSION PROFYLING IN MULTIPLE MYELOMA PATIENTS AS COMPARED TO HEALTHY SUBJECTS: POTENTIAL RELATIONSHIP WITH THE BONE STATUS
K. Todoerti, G. Lisignoli, F. Morandi, L. Agnelli, S. Colla, M. Crugnola,
C. Manferdini, D. Verdelli, K. Codeluppi, G. Lambertenghi-Deliliers,
V. Rizzoli, A. Neri, N. Giuliani (Università di Milano, Fondazione IRCCS Policlinico, Milano, Italy)

0189 THE TYROPHOSTIN ADAPHOSTIN (NSC680410) INHIBITS MULTIPLE MYELOMA BONE MARROW ANGIOGENESIS IN IN VITRO AND IN VIVO
K. Podar, J. Zhang, G. Tonon, M. Sattler, S. Vallet, M.S. Raab,
D. Chauhan, K.C. Anderson (Dana-Farber Cancer Institute, Boston, United States of America)

0190 EARLY CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE IN MM PATIENTS IN CR OR VGPR FOLLOWING AUTOLOGOUS TRANSPLANTATION INDUCES MOLECULAR REMISSIONS
A. Palumbo, F. Cavallo, G. Pagliano, S. Ferrero, L. Santo, V. Magarotto,
P. Pregno, M. Grasso, A.M. Liberati, T. Caravita, F. Pisani, T. Guglielmelli,
C. Crippa, L. De Rosa, D. Drandi, M. Boccadoro, M. Ladetto (A.O.U. San Giovanni Battista, Torino, Italy)

0191 DISTINCT PATHOGENIC SUBGROUPS IN MULTIPLE MYELOMA DEFINED BY QUANTITATIVE GENE EXPRESSION, GENOMIC ABERRATIONS, AND VDJ GENE STRUCTURE
D. Kienle, P. Liebisch, C. Vatter, E. Wiedenmann, A. Brodbeck,
P. Lichter, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0192 EFFECT OF LENALIDOMIDE-BASED REGIMENS ON BONE REMODELING IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
E. Terpos, D. Christoulas, E. Kastritis, E. Katodritou, M.C. Kyrtsonis,
X. Papanikolaou, D. Maltezas, N. Stavropoulos, K. Tsionos, P. Repousis,
G.A. Pangalis, K. Zervas, O. Sezer, M.A. Dimopoulos (251 General Air Force Hospital, Athens, Greece)

0193 GENE EXPRESSION PROFILES FOR MOLECULAR CLASSIFICATION OF MUTLIPLE MYELOMA
A. Broyl, D. Hose, Y. Knegt, de, H. Lokhorst, H. Goldschmidt, M. Duin, van, P. Sonneveld (Erasmusmc, Rotterdam, The Netherlands)

0194 A CELLULAR PROTEOME MAP OF HUMAN MULTIPLE MYELOMA
W. Drach, A. Slany, V. Sagaster, N. Gundacker, V. Haudek, H. Wimmer,
C. Zielinski, C. Gerner (Medical University of Vienna, Vienna, Austria)

0195 SERUM ANGIOPOIETIN-1 TO ANGIOPOIETIN-2 RATIO IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM THE GREEK MYELOMA STUDY GROUP ON 174 PATIENTS
E. Terpos, K. Anargyrou, E. Katodritou, E. Kastritis, A. Pouli, E. Michali,
S. Delimpasi, E. Verrou, D. Margaritis, K. Tsionos, K. Stefanoudaki,
K. Zervas, M.A. Dimopoulos (251 General Air Force Hospital, Athens, Greece)

0196 MICRORNA GENES ASSOCIATED WITH GENOMIC ALTERATIONS OR GENE EXPRESSION MODULATION CONTRIBUTE TO ENHANCE GENETIC HETEROGENEITY IN MULTIPLE MYELOMA
M. Lionetti, L. Mosca, L. Agnelli, D. Ronchetti, S. Fabris, A Andronache, L. Nobili, G. Ciceri, G. Lambertenghi-Deliliers, A. Neri (University of Milan, Fondazione IRCCS Ospedale Policlinico, Milan, Italy)

0197 IDENTIFICATION OF NEOPLASTIC PLASMA CELLS BY FLOW CYTOMETRY: LOOKING FOR THE BEST MARKER(S)
P. Mancuso, A Calleri, P Antoniotti, J Quarna, A Agazzi, S Sammassimo, G Pruneri, G Martinelli, F Bertolini (European Institute of Oncology, Milano, Italy)

0198 MICRO-RNA15A AND MICRO-RNA16 EXPRESSION IN MULTIPLE MYELOMA

1. Corthals, Y. Knegt, de, M. Schoester, H.B. Beverloo, K.H. Lam,
2. Sonneveld (Erasmus University Medical Center, Rotterdam, The Netherlands)

0199 FREQUENCY OF C3435T POLYMORPHISM IN A NORTHERN IRISH POPULATION AND ASSOCIATIONS WITH OVERALL SURVIVAL IN MYELOMA
S. Drain, M.A. Catherwood, M.B. Drake, P.J. Kettle, T.C.M. Morris,
H.D. Alexander (University of Ulster, Coleraine, United Kingdom)

---

0200 VASCULAR ENDOTHELIAL GROWTH FACTOR, OSTEOPONTIN AND NF-AB/P65 EXPRESSION IN MULTIPLE MYELOMA
S. Sˇ tifter, T. Valkovic, A. Nacinovic-Duletic, K. Matusˇ an-Ilijasˇ , K. Lucin,
I. Seili-Bekafigo, D. Rendic Petranovic, N. Jonjic (School of Medicine, Medical University Rijeka, Rijeka, Croatia)

0201 ELEVATED SERUM TIMP-1 LEVELS CORRELATE WITH ADVANCED STAGE AND PREDICT REDUCED SURVIVAL IN NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS
E. Terpos, M.A. Dimopoulos, V. Shrivastava, K. Leitzel, D. Christoulas,
M. Migkou, M. Gavrietopoulou, E. Eleftherakis-Papaiakovou,
K. Anargyrou, E. Kastritis, P. Hamer, W. Carney, A. Lipton (251 General Air Force Hospital, Athens, Greece)

0202 INCREASING FREQUENCY OF MCL-1 MRNA EXPRESSION THROUGH THE STAGES OF MULTIPLE MYELOMA
A.K. Mylin, T. Rasmussen, M. Lodahl, I.M. Dahl, L.M. Knudsen (Rigshospitalet, University of Copenhagen, Copenhagen, Denmark)

0203 MOLECULAR CYTOGENETIC ANALYSIS OF WALDENSTROM’S MACROGLOBULINEMIA IN KOREA
J.W. Seo, S.M. Bang, K.U. Park, S.S. Yoon, D.S. Lee, H.J. Kim,
K.H. Kim, S.R. Cho, H.C. Kim, J.W. Song, J.S. Kim, K.W. Kim, J.H. Lee,
J.J. Lee, M.K. Shin, C. Suh, H.S. Chi, D. Oh, J.H. Won (Seoul National University Hospital, Seoul, South-Korea)

0204 PHENOTYPE OF PLASMA CELLS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA SUBJECTS
L. Kovarova, I. Buresova, R. Suska, L. Pour, L. Zahradova, V. Sandecka,
M. Penka, R. Hajek (University Hospital, Brno, Czech Republic)

---

MULTIPLE MYELOMA - CLINICAL I

0205 INDUCTION WITH CYBORD PRODUCES HIGH COMPLETE RESPONSES IN NEWLY DIAGNOSED MULTIPLE MYELOMA

1. Stewart, B. Reeder, R. Fonseca, P.L. Bergsagel, A. Pirooz,
2. Hentz, E. Boesiger, G. Pisa, V. Kukreti, Ch. Chen, S. Trudel, R. Mikhael,
3. Leis, E. Reece (Mayo Clinic, Scottsdale, USA)

0206 INCORPORATION OF THALIDOMIDE INTO UP-FRONT DOUBLE AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA FAILS TO OVERCOME THE POOR PROGNOSIS IMPARTED BY CHROMOSOME 13 DELETION
M. Cavo, C. Terragna, N. Testoni, P. Tosi, M. Ceccolini, A. Gorgone,
S. Annunziata, C. Nicci, M. Renzulli, P.P. Fattori, G. Leopardi, E. Zamagni,
P. Tacchetti, G. Perrone, S. Ronconi, A. Lazzaro, M. Offidani, M. Fiacchini,
D. Vertone, P. Fabbri, A. Brioli, M. Pallotti, L. Pantani, L. Guardigni,
D. Mamone, M. Baccarani ("Seràgnoli" Institute of Hematology and Medical Oncology, Bologna, Italy)

0207 PROLONGED THERAPY WITH BORTEZOMIB PLUS MELPHALAN– PREDNISONE (VMP) RESULTS IN IMPROVED QUALITY AND DURATION OF RESPONSE IN THE PHASE III VISTA STUDY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM)
A. Palumbo, R. Schlag, N. Khuageva, O. Shpilberg, M. Dimopoulos,
M. Kropff, I. Spicka, M. Petrucci, M. Delforge, M. Mateos, D. Esseltine,
K. Liu, W. Deraedt, H. Van de Velde, P. Richardson, J. San-Miguel (Divisione di Ematologia dell’Universita di Torino, Torino, Italy)

0208 BORTEZOMIB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND THALIDOMIDE (VDT) FOR THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA
S. . Ailawadhi, K.C. Miller, D. Depaolo, A. Whitworth, J. Yu, D.L. Trump,
S. Padmanabhan, M. Czuczman, Z.P. Bernstein, F. Hernandez-Ilizaliturri,
K. Lee, A. Chanan-Khan (Roswell Park Cancer Institute, Buffalo, USA)

0209 A RANDOMISED PLACEBO CONTROLLED STUDY WITH MELPHALAN/PREDNISONE VERSUS MELPHALAN/PREDNISONE/ THALIDOMIDE: QUALITY OF LIFE AND TOXICITY
N. Gulbrandsen, A. Waage, P. Gimsing, I. Turesson, G. Juliusson,
N. Abildgaard, B. Bjørkstrand, K. Carlson, I.M. Dahl, K. Forsberg,

1. Knudsen, J. Lanng Nielsen, U.H. Mellqvist, I. Nesthus, M. Strandberg,
2. Wisløff, P. Fayers (Ullevål University Hospital, Oslo, Norway)

0210 BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY
M. Gentile, S. Ciolli, M.T. Petrucci, S. Galimberti, G Mele, A.F. Casulli,
D. Mannina, E. Piro, F. Morabito (Ematologia di Cosenza, Cosenza, Italy)

0211 A MULTICENTER COMPARISON OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWED BY REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION WITH TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA :THE KOREAN MULTIPLE MYEOMA WORKING PARTY (KMMWP)
C.K. Min, H. Kim, K. Kim, J.Y. Kwak, S.T. Lee, J.H. Won, S.S. Yoon,
J.H. Lee, C. Suh (St. Mary's Hospital, The Catholic University of Korea, Seoul, South-Korea)

0212 INFLUENCE OF GLUCOCORTICOID RECEPTOR POLYMORPHISM G+647C ON EFFICACY OF VAD AND VD THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
N.V. Stepanova, A. Voitovich, V. Larionova, S. Moiseev (St.-Petersburg State Medical Uniersity, Saint-petersburg, Russian Federation)

0213 MELPHALAN, PREDNISONE AND LENALIDOMIDE FOR NEWLY DIAGNOSED MYELOMA: KINETICS OF NEUTROPENIA/ THROMBOCYTOPENIA AND TIME TO EVENT RESULTS
A. Palumbo, P. Falco, P. Corradini, C. Crippa, F. Di Raimondo,
A. Falcone, N. Giuliani, P. Musto, P. Pregno, G. Aitoro, A. Luraschi,
A. Nozza, R. Knight, J.B. Zeldis, M. Boccadoro, M.T. Petrucci (A.O.U. San Giovanni Battista, Torino, Italy)

0214 A PILOT STUDY TO EXPLORE THE TOLERABILITY AND EFFICACY OF THALIDOMIDE CONTAINING REGIMENS TO REDUCE TUMOUR CELL LOAD PRIOR TO AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA (MM)
N. Horvath, D. Joshua, J. Gibson, A. Roberts, J. Norman, C. Underhill,
C. To, L.B. To (IMVS, Adelaide, Australia)

0215 SEQUENTIAL VAD (VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) AND VTD (BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE TREATMENT WITH BORTEZOMIB FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM RESULTS OF PHASE II TRIAL
S.S. Yoon, H.J. Kim, D.S. Lee, H.S. Eom, J.H. Jang, J.S. Chung,
H.J. Kang, C.S. Kim, K.K. Kim, J.H. Lee, S.J. Lee, Y.H. Min,
C.M. Seong, S.K. Sohn, C. Suh, J.H. Won (Seoul National University Hospital, Seoul, South-Korea)

0216 LONG-TERM OUTCOMES OF AUTOLOGOUS TRANSPLANTATION IN 141 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
M. Krejci, R. Hajek, Z. Adam, A. Krivanova, L. Pour, K. Kresova,
M. Holanek, V. Sandecka, M. Sahmani, J. Mayer, J. Vorlicek (IHOK University Hospital Brno and IHOK LF MU Brno, Brno, Czech Republic)

0217 RETROSPECTIVE COMPARISON OF BORTEZOMIB WITH VINCRISTINE-DOXORUBICIN-DEXAMETHASONE (VAD) AS INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
C.K. Min, B,S. Cho, S. Lee, K.S. Eom, J.W. Lee, W.S. Min, C.W. Park,
C.C. Kim (St. Mary's Hospital, The Catholic University of Korea, Seoul, South-Korea)

0218 VTD (VELCADE, THALIDOMIDE, DEXAMETHASON) REPRESENTS AN ACTIVE INDUCTION REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA
W. Drach, V. Odelga, J. Ackermann, V. Sagaster, H. Kaufmann, N. Worel,
W. Rabitsch, P. Kalhs, C. Zielinski (Medical University of Vienna, Vienna, Austria)

0219 VTD INDUCTION CHEMOTHERAPY FOLLOWED BY MPT MAINTENANCE AS A FIRST LINE TREATMENT FOR THE PATIENTS WITH MULTIPLE MYELOMA WHO ARE NON-TRANSPLANT CANDIDATES
H.S. Eom, Y.K. Kim, J.S. Chung, K.H. Kim, H.J. Kim, J.Y. Jin, Y.R. Do,
S.J. Oh, H.Y. Kim, C.W. Suh, C.M. Seong, C.S. Kim, D.S. Lee, J.H. Lee (National Cancer Center, Goyang-si, Gyeonggi-do, South-Korea)

0220 THADD REGIMEN IS FEASIBLE AND EFFECTIVE IN AN UNSELECTED MULTIPLE MYELOMA POPULATION AGED 75 OR MORE YEARS
M. Offidani, L. Corvatta, C. Polloni, M.-N. Piersantelli, S. Gentili, P. Galieni,
M. Catarini, A. Mele, M. Brunori, A. Samori, G. Visani, N. Blasi, M. Ferranti,
F. Alesiani, M. Burattini, R. Centurioni, P. Leoni (Clinica Ematologia, Ancona, Italy)

0221 SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION
M. Postorino, L. Pupo, L. Di Caprio, S. Campagna, L. Franceschini,
D. Renzi, M. Rizzo, L. Gianni, S. Faccia, R. Cannarsa, M. Ales,
F. Buccisano, D. Venditti, M. Cantonetti, S. Amadori (Tor Vergata University, Rome, Italy)

0222 PROMISING THERAPY RESPONSE IN MULTIPLE MYELOMA PATIENTS TREATED WITH INDUCTION CHEMOTHERAPY CONSISTING OF BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
W. Zinke-Cerwenka, T. Stojakovic, H. Sill, E. Eibl, W. Linkesch (Division of Hematology, Graz, Austria)

0223 A COMPARISON OF TWO CONDITIONING REGIMENS FOR MULTIPLE MYEOLOMA. A SINGLE CENTER EXPERIENCE
J. Peñarrubia, R. Cuello, A. Cantalapiedra, A. Dueñas, E. Fontecha,
O. Gutierrez, A. Silvestre, J.M. Martin-Antoran, J. Fernández-Calvo,
J. García-Frade (Hospital del Rio Hortega, Valladolid, Spain)

---

MYELODYSPLASTIC SYNDROMES - CLINICAL I

0224 EFFECT OF AZACITIDINE (AZA) VERSUS LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
P. Fenaux, N. Gattermann, J. Seymour, E. Hellström-Lindberg,

1. Mufti, U. Duehrsen, S. Gore, F. Ramos, O. Beyne-Rauzy,
2. Dombret, A. List, D. McKenzie, J. Backstrom, A. Allen, C.L. Beach (Hôpital Avicenne, Bobigney, France)

0225 A PHASE II STUDY OF OUTPATIENT ADMINISTRATION OF DECITABINE FOR 5 DAYS EVERY 4 WEEKS TO ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
P. Steensma, M. Baer, J. Slack, R. Buckstein, L. Godley, J. Larsen,
M. Cullen, S. Arora, H. Kantarjian (Mayo Clinic, Rochester, Mn, USA)

0226 WELL-DIFFERENTIATED SYSTEMIC MASTOCYTOSIS (WDSM): A NOVEL FORM OF MASTOCYTOSIS
M. Jara-Acevedo, A.C. García-Montero, C. Teodosio, L. Escribano,
I. Alvarez, L. Sanchez-Muñoz, C. Akin, D.D. Metcalfe, A. Orfao (Cancer Research Center, Salamanca, Spain)

0227 5-AZA-2’-DEOXYCYTIDINE CAN INDUCE DIFFERENTIATION OF CLONAL ABNORMAL PROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT INDUCTION OF APOPTOSIS
S. Meers, P. Vandenberghe, M. Boogaerts, G. Verhoef, C. Verfaillie,
M. Delforge (University Hospital Leuven, Leuven, Belgium)

0228 IRON CHELATION THERAPY WITH DEFERASIROX (ICL670) REDUCES SERUM FERRITIN (SF) AND LABILE PLASMA IRON (LPI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

1. List, M.R. Baer, D. Steensma, A. Raza, J. Esposito, J. Virkus,
2. Feigert, E. Besa, C. Paley (University of South Florida, Tampa, USA)

0229 TRANSFUSION BURDEN, DISEASE DURATION AND AGE IDENTIFY NON-DELETION 5Q MDS PATIENTS HIGHLY RESPONSIVE TO LENALIDOMIDE TREATMENT
A.F. List, K. Wride, R. Knight (University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA)

0230 A NEW EVALUATION OF THE POTENTIAL AETIOLOGICAL ROLE OF SMOKING HABIT IN PRIMARY MYELODYSPLASTIC SYNDROME: INBIOMED HEMA-001/2004 STUDY (PART ONE)
F. Ramos, N. De Las Heras, J.A. Rodriguez, M. Megido, J.R. Gonzalez,
L. Florensa, M. Barbon, C. Del Canizo, M. Fuertes, J. Gonzalez-Gallego (Hospital de León, León, Spain)

0231 5-AZACYTIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA: RESULTS IN 45 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
P. Musto, L. Maurillo, A. Spagnoli, M. Genuardi, M. Lunghi, N. Di Renzo,
G. Mele, A. Levis, A. D'Arco, A. Gozzini, M. Petrini, M. Mianulli,
G. Sanpaolo, A. Santagostino, G. Pietrantuono, F. D'Auria, D. Ferrero,
G. Gaidano, F. Ferrara, V. Santini, G. Leone, A. Bosi, A. Venditti (CROB, Centro di Riferimento Oncologico della Basilicata, Rionero In Vulture (pz), Italy)

0232 RAPID ONSET OF EFFECTIVENESS WITH THREE ALTERNATIVE AZACITIDINE (AZA) DOSING REGIMENS IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)
R. Lyons, T. Cosgriff, S. Modi, H. McIntyre, I. Fernando, J. Backstrom,
C.L. Beach (Cancer Care Centers of South Texas, San Antonio, USA)

0233 TREATMENT-RELATED MYELODYSPLASIA AND SECONDARY AML FOLLOWING FLUDARABINE COMBINATION CHEMOTHERAPY
A. Carney, A. Westerman, S. Tam, A. Milner, H. Prince, M. Kenealy,
M. Wolf, E. Januszewicz, A. Ritchie, N. Came, F. Seymour (Peter MacCallum Cancer Centre, East Melbourne, Australia)

0234 TREATMENT WITH VNP40101M (CLORETAZINE®) IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF A SUBSET POPULATION IN A PHASE II STUDY
G. Mufti, D. Rizzieri, N. Vey, D. Hudak, J. Karp, F. Giles (King's College Hospital, London, United Kingdom)

0235 PRE-TRANSPLANT SERUM FERRITIN AS AN INDEPENDENT PROGNOSTIC FACTOR IN MDS PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING HSCT
Z.Y. Lim, V.F. Fiaccadori, S.G. Gandhi, M. Kenyon, A.Y.L. Ho,
A.P. Pagliuca, G.J. Mufti (Kings College London and Kings College Hospital, London, United Kingdom)

0236 EUROPEAN INTER-COUNTRY TREATMENT SELECTION DIFFERENCES DO NOT ALTER OVERALL SURVIVAL BENEFIT SHOWN WITH AZACITIDINE VS CONVENTIONAL CARE REGIMENS IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
V. Santini, P. Fenaux, N. Vey, W.K. Hofmann, T. Robak, A. Bacigalupo,
L. Silverman, M. Canales, N. Scmitz, P. Muus, I. Fernando, J. Backstrom,
L. Zimmerman, C.L. Beach (University of Florence, Firenze, Italy)

0237 TREATMENT OF LOWER RISK MDS WITH DEL 5Q WITH LENALIDOMIDE (LEN): CURRENT RESULTS OF THE FRENCH PATIENT NAMED PROGRAM (ATU)
F. Le Bras, M. Sebert, V. Eclache, T. Lamy, J. Dlaunay, S. Visanica,
F. Dreyfus, A. Banos, M. Blanc, C. Leyronnas, C. Besson, B. Derenzis,
X. Thomas, C. Rodon, N. Vey, M. Gardembas, M. Faron, F. Bauduer,

1. Ramee, D. Zajec, A. Delmer, D. Rea, O. Beyne-Rauzy, J. Ceccaldi,
2. Beaucournou, J. Dugay, P. Fenaux, L. Ades (AP HP, Paris, France)

0238 5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
L. Maurillo, A. Spagnoli, A. Gozzini, N. Cecconi, M. D'Argenio,
M. Lunghi, S. Rocco, G. Palumbo, F. Rivellini, M. Genuardi, S. Sibilla,
F. Ferrara, G. Mele, N. Filardi, G. Sanpaolo, G. Specchia, A. Tonso,
A. Santagostino, M.T. Voso, E. Balleari, V. Cassibba, P. Della Cioppa,
C. Mazzone, E. Oliva, L. Ciuffreda, D. Russo, S. Galimberti, O. Villani,
F. D'Auria, N. Di Renzo, A.M. D'Arco, F. Di Raimondo, G. Gaidano,
D. Ferrero, V. Pavone, A. Venditti, V. Santini, P. Musto (S. Eugenio Hospital, Tor Vergata Univerdsity, Rome, Italy)

0239 MONOCYTES FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES ARE MORE RESISTANT TO THALIDOMIDE­MEDIATED TNF-ALPHA INHIBITION COMPARED TO MONOCYTES FROM CONTROL SUBJECTS
S. Meers, L. Boon, M. Boogaerts, C. Verfaillie, G. Verhoef, M. Delforge (University Hospital Leuven, Leuven, Belgium)

0240 THE ORAL CHELATOR ICL670 REPRESSES SIGNALING THROUGH THE MTOR PATHWAY IN MYELOID LEUKEMIA CELLS BY ENHANCING EXPRESSION OF REDD1
J. Ohyashiki, C. Kobayashi, R. Kurashina, Y. Zhang, R.S. Hamamura,
K. Ohyashiki (Tokyo Medical University, Tokyo, Japan)

0241 ALL-TRANS RETINOIC ACID (ATRA) COMBINED TO ERYTHROPOIETIN (EPO) FOR THE TREATMENT OF ANEMIA IN LOW RISK MYELODYSPLASTIC SYNDROMES (MDS)
R. Itzykson, S. Ayari, D. Vassilief, E. Berger, B. Slama, N. Vey, F. Suarez,
O. Beyne-Rauzy, A. Guerci, S. Cheze, X. Thomas, A. Stamatoullas,
M. Gardembas, F. Bauduer, M.C. Chaury, A. Kolb, L. Legros, D. Damaj,
F. Hamza, F. Dreyfus, P. Fenaux, L. Ades (Assistance Publique Hopitaux de Paris - Hopital Avicenne - Universite Paris 13, Bobigny, France)

---

NON-HODGKIN'S LYMPHOMA - BIOLOGY AND CLINICAL

0242 GENOME-WIDE ANALYSIS OF DIFFERENT SUBTYPES OF B-CELL NON-HODGKIN’S LYMPHOMA USING HIGH-RESOLUTION GENOMIC MICROARRAYS
M. Kato, K. Takeuchi, G. Yamamoto, Y. Nannya, M. Sanada, S. Chiba,
Y. Ishikawa, S. Mori, Y. Kobayashi, M. Kurokawa, S. Ogawa (The University of Tokyo Hospital, Tokyo, Japan)

0243 CHLAMYDOPHILA PSITTACI (CP) IS VIABLE AND INFECTIOUS IN THE CONJUNCTIVA AND PERIPHERAL BLOOD OF PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML): RESULTS OF A PROSPECTIVE CASE-CONTROL STUDY

1. Ferreri, R. Dolcetti, P. Dognini, L. Malabarba, N. Vicari, E. Pasini,
2. Ponzoni, M.G. Cangi, L. Pecciarini, A. Giordano Resti, S. Rossini,
3. Doglioni, S. Magnino (San Raffaele H Scientific Institute, Milan, Italy)

0244 PATTERN OF ANGIOGENESIS-RELATED GENE EXPRESSION DURING IN VIVO GROWTH OF MANTLE CELL LYMPHOMA CELL LINE JEKO-1
J.M. Molinsky, S.L Leahomschi, M.H. Hulova, T.S. Simonova,
R.P. Pytlik, M.T. Trneny, T.S. Soukup, J.M. Mokry, E.N. Necas,
J.Z. Zivny, P.K. Klener (Charles University in Prague, 1st Faculty of Medicine, Praha 2, Czech Republic)

0245 CRYPTIC REARRANGEMENTS OF THE ALK GENE IN ALK-EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMA
K. Van Roosbroeck, J. Cools, D. Dierickx, J. Thomas, P. Vandenberghe,
P. Marynen, J. Delabie, C. De Wolf-Peeters, I. Wlodarska (Department of Human Genetics, Catholic University of Leuven, Leuven, Belgium)

0246 EXPRESSION OF CXCR4 AND CD26 ON DENDRITIC LYMPHOPLASMACYTOID LYMPHOMA: A KEY FOR INTERPRETING SKIN HOMING OF NEOPLASTIC CELLS
L. Del Vecchio, R. Franco, A. De Renzo, G. Cerciello, F. Perna, C. Lo Pardo, V. Mettivier, A.M. D'Arco, G. Corazzelli, P Mirabelli, G. Abate,
M. Gorrese, B. Rotoli (CEINGE Institute, Naples, Italy)

0247 FACS SORTING IS AN EFFICIENT, FLEXIBLE AND CONVENIENT CELL TARGETING STRATEGY: APPLICATIONS IN ROUTINE MOLECULAR DIAGNOSTICS OF MATURE B-CELL MALIGNANCIES
B. Maes, K. Hensen, F. Hillen, V. Peeters, J.-L. Rummens (Virga Jesse Hospital, Hasselt, Belgium)

0248 THE HAEMOPHAGOCYTIC SYNDROME (HPS) RE-VISITED: A SOUTHEAST ASIAN PERSPECTIVE
C. Tan, W. Hwang, Y. Loh, C. Chuah, H.J. Ng, L.H. Lee, S.L. Tien, L.C. Lim,
Y.T. Goh, M. Koh (Singapore General Hospital, Singapore, Singapore)

0249 TRANSCRIPTOME DEFINED PATHOGENESIS AND CLASSIFICATION OF B-CELL NON-HODGKIN LYMPHOMAS IDENTIFIES SIGNATURES THAT PROVIDE AVENUES FOR PROGNOSTIC MARKERS AND GENOMIC DRIVEN TARGETED THERAPIES
M. Aggarwal, M.A. Piris, E. Kimby (Spanish National Cancer Center, Madrid, Spain)

0250 FOLLICULAR LYMPHOMA (FL) DIFFERS FROM FOLLICULAR HYPERPLASIA (FH) ALSO AT THE EPIGENETIC LEVEL
J. Paz Carreira, R. Losada, A. Garcia-Rivero, M. Varela-Pérez,
A. Alvarez, F. Bal, J. Alba, M. Gonzalez-López (Centro Oncologico de Galicia, La Coruña, Spain)

0251 CUTANEOUS CCL27 EXPRESSION IN EARLY-STAGE MYCOSIS FUNGOIDES: ITS ROLE IN THE BALANCE BETWEEN THE TUMORAL INFILTRATE AND ANTI-TUMORAL IMMUNE RESPONSE, AND PROGNOSTIC UTILITY AS A PREDICTOR OF RECURRENCE
G. Goteri, S. Rupoli, A. Campanati, S. Sabato, L . Canafoglia,
G. Ganzetti, P. Picardi, A. Costagliola, D. Stramazzotti, S. Pulini,
A.R. Scortechini, S. Serresi, M. Ottaviani, M. Nicolini, A. Cellini, G. Fabris,
A.M. Offidani, P. Leoni (Institute of Pathology, Ancona, Italy)

0252 MUTATION ANALYSIS OF IGVH GENES IN 18 SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) CASES AND CORRELATION WITH CLINICAL AND IMMUNOPHENOTYPIC CHARACTERISTICS
C. Kalpadakis, E. Dimitriadou, T. Vassilakopoulos, M. Angelopoulou,
M. Siakantaris, F. Kontopidou, H. Papadaki, P. Panayiotidis,
G. Pangalis (University of Crete, Heraklion, Greece)

0253 LONG-TERM SURVIVAL OF PATIENTS DIAGNOSED WITH NON-HODGKIN LYMPHOMA AFTER A PREVIOUS MALIGNANCY
D. Pulte, A. Gondos, H. Brenner (Weill Cornell Medical College, New York, USA)

0254 NT-PROBNP IS A POWERFUL AND INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN ANTHRACYCLIN-TREATED LYMPHOMA PATIENTS
A. Salar, R Guerri, J Comín, A. Alvarez-Larrán, M Gomez, E. Gimeno, B Sanchez-Gonzalez, C. Pedro, E. Abella, L Molina, T. Gimenez, J Bruguera, C. Beses (Hospital del Mar, Barcelona, Spain)

0255 T-CELL LARGE GRANULAR LYMPHOCYTE LEUKAEMIA: CLINICAL COURSE AND RESPONSE TO TREATMENT
F. Fortune, A. Fortune*, K. Kelly*, J. Sargent, S. McGuckin, F. Quinn,
K. Haslam, D. O'Brien, E. Conneally, P. Browne, P. Thornton,
E. Vandenberghe (St. James Hospital, Dublin, Ireland)

0256 HYPOGAMMAGLOBULINEMIA AND NON-NEUTROPENIC INFECTION AFTER CHEMOTHERAPY COMBINED WITH RITUXIMAB. PREDICTIVE FACTORS AND CLINICAL SIGNIFICANCE
L. Shvidel, K. Filanovsky, M Shtalrid, A. Duek, M. Haran, E. Sigler,
A. Berrebi (Kaplan Medical Center, Rehovot, Israel)

0257 INTERLEUKIN 10 (IL10) PROMOTER POLYMORPHISMS ARE ASSOCIATED TO THE EPSTEIN-BARR VIRUS STATUS IN CHILDHOOD BURKITT’S LYMPHOMA: PATHOGENIC CLUES FROM AN INTERMEDIATE RISK REGION
C. F. M. Fonseca Minnicelli, M.H.M. Barros, I.Z. Zalcberg, R.H. Hassan (National Institute of Cancer, Rio De Janeiro, Brazil)

0258 RISK OF FEBRILE NEUTROPENIA AND USE OF G-CSF PRIMARY PROPHYLAXIS IN NON-HODGKIN’S LYMPHOMA PATIENTS RECEIVING R-CHOP-21
C. Haioun, U. Jaeger, P. Lugtenburg, R. Pettengell, F. Principe, F. Rossi,
A. Salar, M. Schwenkglenks, G. Verhoef, S. Edmundson, P. Bacon (CHU Henri Mondor, Creteil, France)

---

NON-HODGKIN'S LYMPHOMA – CLINICAL (INDOLENT + MISCELLANEOUS)

0259 THE (R)VAD+C REGIMEN IS A GOOD PREPARATIVE REGIMEN BEFORE PBSC TRANSPLANTATION FOR MCL PATIENTS TREATED IN FIRST LINE AND KI67 APPEARS AS AN EFFECTIVE INDEPENDANT FACTOR OF SURVIVAL: TEN YEARS EXPERIENCE OF THE FRENCH GOELAMS GROUP
R. Gressin, S. Caulet Maugendre, E. Deconinck, O. Tournilhac,
M. Dartigeas, M.P. Moles, J. Dugay, D. Guyotat, J.F. Rossi, S. Le Gouill,
G. Lepeu, G. Damaj, T. Lamy, P. Solal Celigny, H. Maisonneuve,
B. Corront, J.P. Vilque, P. Casassus, J.L. Dutel, J.P. De Jaurreguyberry,
F. Maloisel, P. Rodon, A. Thyss, P. Feugier, C. Le Maignan, S. Cailleres,
V. Lucas, i. Grulois, A. Bellange, M. Colonna, P. Colombat, E. Gyan (CHU Michallon, Grenoble, France)

0260 PROLONGED SURVIVAL IN REFRACTORY/RELAPSED MANTLE CELL LYMPHOMA FOLLOWING EARLY-INTENSIFIED CHEMOTHERAPY WITH MULTIPLE AUTOLOGOUS HEMATOPOIETIC STEM CELL SUPPORT
S.C. C